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Breast cancer results in significant mortality and morbidity across the world. In Asia, the 
burden of breast cancer is increasing at a rapid rate due to increasing incidence rates. 
Survival rates on the other hand vary based on levels of economic development for Asian 
countries. This thesis focuses on the clinical outcome of breast cancer patients from 
Singapore and Malaysia. Data for the studies was obtained from the Singapore Malaysia 
Breast Cancer Working Group (SMBCWG) Hospital based Breast Cancer Registry [1]. 
In order to estimate the differences in presentation, treatment and outcome of breast 
cancer patients between a middle income and a high income country in SE Asia, we 
compared patients from Malaysia and Singapore, two SE Asian countries with varying 
levels of economic development. The results from this study indicate that differences in 
way of presentation and treatment of patients from Singapore and Malaysia with breast 
cancer were present, but small. Patients from Malaysia present slightly more often with 
advanced stage and unfavorable tumor characteristics, however, the overall survival of 
breast cancer patients from Malaysia was much lower (Adjusted Hazard Ratio 1.6, 95% 
CI 1.4 to 1.8) than that of Singaporean patients. Poorer compliance with treatment, 
unfavorable life style factors and competing risks could potentially explain the higher 
mortality risk of Malaysian breast cancer patients. 
In order to quantify the excess mortality among Singaporean breast cancer patients, we 
conducted a comparison study with Surveillance Epidemiology and End Results (SEER - 
USA) breast cancer patients. Overall 5-year relative survival was higher for SEER 
patients than Singaporeans especially for late stage disease and all age groups. Had the 
SEER stage-specific relative survival rates been reached in Singapore, 410 instead of an 
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estimated 529 breast cancer deaths would have been observed (reduction of 22.4%). 
Much of the survival differences can be explained by differences in stage at diagnosis, 
which could be due to lower disease awareness and the low uptake of the mammography 
screening program in Singapore. 
The prognostic value of a new indicator, namely, the Lymph Node Ratio (LNR – ratio of 
the number of positive to the total number of axillary nodes removed) was evaluated and 
compared to the current pN staging in both the neoadjuvant and adjuvant chemotherapy 
setting. Both LNR and pN staging were equally good in predicting all cause mortality for 
patients receiving neoadjuvant chemotherapy. In the adjuvant setting, LNR was superior 
to pN in categorizing mortality risks for women ≥ 60 years, those with Estrogen Receptor 
(ER) negative or grade 3 tumors. In combination with other factors (i.e. age, treatment, 
grade, tumor size and receptor status), substituting pN by LNR did not result in better 
discrimination of women at high versus low risk of death, neither for the entire cohort (c 
statistic 0.72 [0.70-0.75] and 0.73 [0.71-0.76] respectively for pN versus LNR), nor for 
the subgroups mentioned above.  
With the increasing incidence of breast cancer in general, the shift towards the older age 
groups and the aging population of Singapore (the median age of the Singaporean 
population is currently in the late thirties, but by the year 2050, the majority Singapore 
women will be ≥65 years of age), it is crucial to have a good understanding of breast 
cancer in older Singaporean women. This study showed that older Singaporean women 
were more often diagnosed with advanced stages and estrogen receptor positive tumors. 
They were less likely to have undergone an axillary clearance, radiotherapy post breast 
conserving surgery and chemotherapy for lymph node positive disease. Older women had 
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poorer relative survival than younger women; however these differences largely 
disappeared after stage stratification. 
In summary, breast cancer patients from Singapore and Malaysia have substantial 
differences in terms of overall survival which are not completely explained by tumor 
characteristics and treatment differences. Elderly Singaporean patients present with more 
advanced disease and are less likely to receive adequate treatment compared to younger 
Singaporean patients. Singaporean patients overall still have some way to go before they 
can achieve survival rates seen for the SEER patients which can partly be achieved by 
early detection / presentation. Lastly, based on the results from the LNR studies, it is 
clear that LNR does not add any prognostic value over the current pN staging system for 
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Chapter 1 Introduction 
 
With a million new cases of breast cancer each year, breast cancer is the most common 
type of cancer and the most common cause of cancer deaths among women worldwide 
[2, 3]. In contrast to Europe and the US, where breast cancer incidence rates have 
stabilized or even decreased, Asian breast cancer rates are increasing dramatically [4-7]. 
The rise in incidence observed in Asia is attributed in part to the trend for young Asian 
women to adopt western lifestyles [1]. Coupled with this, the sheer increase in the 
absolute number of women in countries like India and China, makes it reasonable to 
assume that in the relatively near future, the majority of breast cancer patients will be of 
Asian ethnicity. Despite this, there is a lack of good quality breast cancer data with long 
term follow up on Asian breast cancer patients and thus little is known about the 
presentation, management and outcome of breast cancer among multi-ethnic Asian 
women. Extending breast cancer research into Asia is very much needed as the Western 
based knowledge of breast cancer etiology [8], diagnosis [9], prognosis [10] and 
treatment [11] cannot be simply transferred to the Asian population. Asian women have 
different genetic make-up, ethnicity, lifestyle, cultures, diet and health beliefs compared 
to their Western counterparts and as such, each of these may play a distinct role in breast 
cancer incidence, prognosis and treatment. Healthcare systems are also different in Asia 
with limited resources thus requiring different approaches towards preventive strategies 
and treatment of breast cancer [12].  
South East Asia (SEA) which sees a diversity of ethnic subgroups with distinct genetic, 
cultural and lifestyle profiles was recently highlighted as an emerging focus for global 
health [13]. Keeping this in mind, it is important to fill the knowledge gap pertaining to 
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breast cancer in SEA, especially Singapore and Malaysia, where data is more readily 
available and most of the work presented in this thesis is the first result of an initiative to 
fill this void. 
 Outline of the thesis 
The Singapore Malaysia Breast Cancer Working Group (SMBCWG) was established in 
November 2009 with the aim of improving the understanding of breast cancer in the 
region of SEA. This was a joint effort on the part of  epidemiologists, oncologists and 
breast surgeons from two tertiary teaching hospitals, namely, the National University 
Hospital (NUH), Singapore and University of Malaya Medical Center, Malaysia 
(UMMC) [1]. Under this international, multidisciplinary collaboration, the breast cancer 
registries of the above mentioned hospitals were merged to form an international hospital 
based breast cancer registry. 
The first section of the thesis focuses on a detailed literature review (Chapter 2). This 
chapter discusses what is known about breast cancer in South East Asia, particularly 
focusing on Singapore and Malaysia and provides a detailed write up on screening, 
clinical investigation and survival of breast cancer patients. Keeping in mind, the core 
research component of this thesis, a detailed description of the various prognostic 
indicators for breast cancer is also discussed. 
Chapter 3 discusses the key epidemiological concepts that were taken into consideration 
while analyzing the data as well as the statistical methods used throughout the studies and 
their significance towards the analysis.  
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Globally, the burden of breast cancer is increasing with an estimated 1.7 million new 
cases of breast cancer by 2020, the majority of which will arise from Asian countries 
[14]. Chapter 4 explores the differences in presentation, treatment and survival between 
breast cancer patients from a high income country (Singapore) and a middle income 
country (Malaysia). Additionally, the excess mortality among Singaporean breast cancer 
patients is quantified by comparing survival between Singaporean and SEER (USA) 
breast cancer patients. 
Breast cancer is a disease of the elderly [15, 16] with a majority of Caucasian patients 
being over 65 years of age at diagnosis [17, 18]. Chapter 5 investigates differences in 
tumor characteristics, treatment and survival among older (≥ 65 years) and younger (< 65 
years) female breast cancer patients from Singapore. 
Axillary lymph node status is one of the most important prognostic factors for breast 
cancer [19-21]. Existing evidence suggests that the Lymph Node Ratio (LNR) (the ratio 
of the number of positive nodes to the total number of nodes excised), could be a superior 
prognostic indicator compared to the absolute number of nodes involved [22-26]. 
Chapter 6 studies the Lymph Node Ratio (LNR) as a potential prognostic indicator for 
Singaporean and Malaysian patients in both the neoadjuvant and adjuvant chemotherapy 







Chapter 2 Literature review 
 
Accurately maintained population based and hospital based breast cancer registries 
provide an efficient and useful source of data for analysis. This review focuses on the 
clinical workup, treatment, survival as well as prognostic indicators for breast cancer with 
special attention being paid to breast cancer in Singapore and Malaysia. 
Breast cancer in South East Asia 
Developing countries have seen a rapid rise in breast cancer incidence over the past few 
decades in comparison to developed countries where breast cancer incidence has grown 
at a slower rate [16]. Mortality rates on the other hand have been fairly stable between 
1960 to 1990 in most of Europe and Americas after which they showed an appreciable 
decline [16, 27, 28]. 
In Asia, breast cancer is the commonest cancer among women [29, 30]. Several 
differences between SE Asian and Western breast cancer patients exist. The incidence 
rates of breast cancer in SE Asia are lower than those seen in Western countries (Table 
2.1a and 2.1b). Breast cancer onset in SE Asian women is at a much younger age (mid 
40s) as compared to the West where a majority of the cases arise after 60 years of age 
[30, 31], and unlike the West, the age-specific incidence rates in Asia decrease after the 
age of 50 years [32]. However, due to the aging Asian population and a shift towards the 
older age groups, it is quite likely that the median age of onset for breast cancer in Asia 
will mimic that seen in the West in the years to come. Due to the lack of a population 
based screening program in most SE Asian countries [33, 34], the majority of patients 
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present with advanced disease [1, 30]. There is a higher proportion of hormone receptor-
negative patients, and some evidence that the cancers in Asia are of a higher grade [35].  
Table 2.1a Incidence rates of breast cancer by geographic region. 
*weighted average of the age specific rates for each of the populations with respect to the 
world population. 
Source: Breast Cancer Epidemiology, Chapter 1. Ferlay et al. (2009) 
 
Table 2.1b Age Standardized Incidence and Mortality rates of breast cancer in South 
East Asia (for year 2008) 
Country 
 
Incidence Rate* Mortality Rate* 
Entire SE Asia 31.0 13.4 
Brunei 21.5 17.8 
Burma 32.5 12.2 
Cambodia 20.7 8.0 
East Timor 29.6 17.3 
Indonesia 36.2 18.6 
Malaysia 37.0 14.7 
Philippines 31.9 11.9 
Singapore 59.9 13.6 
Thailand 30.7 10.8 
Vietnam 15.6 5.7 
* per 100,000 person years 
Source: GLOBOCAN 2008 website (globocan.iarc.fr) 
Location Incidence 
Numbers Age Standardized Rate 
(weighted)* per 100,000 
World 1,151,300 37.4 
Northern America 229,600 99.4 
Europe 360,700 62.3 
Australia and New Zealand 13,500 84.6 
Japan and Korea 37,800 30.0 
All more developed 641,600 67.8 
China 126,200 18.7 
India 83,000 19.1 
Latin America & Caribbean 96,600 40.3 
Northern Africa & Western Asia 41,800 28.6 
Sub-Saharan Africa 48,600 23.5 
Other developing 113,500 23.6 
All less developed 509,700 23.8 
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Singapore has the highest incidence rates for breast cancer in SE Asia (Table 2.1b) [36]. 
Breast cancer is the most common form of cancer among Singaporean women and 
accounts for 29.7% of all female cancers in Singapore [37]. Incidence rates in Singapore 
showed an almost three fold increase from 1968 to 2007 (Figure 2.1). Incidence rates for 
breast cancer differed across the three major ethnic groups namely Chinese, Malay  and 
Indian in Singapore [5]. In the 1970s, Indian women had the highest incidence rates but 
by the mid1980s, the highest rates were seen among the Chinese [5]. Today a 
Singaporean woman has a lifetime risk of 1 in 20 to develop breast cancer [38]. There has 
been a shift in the peak age of incidence from the mid forties to the late fifties (Figure 
2.2) and this can partially be attributed to the cohort effect [39]. 
The age standardized incidence rates for all three ethnic groups of Singapore (Chinese, 
Malay and Indian) steadily increased from 1968 to 2002 [5, 40]. Possible reasons for this 
could be the transition of Singapore from an industrialized to a developed country, 
lifestyle changes among the Singaporean women, delayed child bearing and reduction in 
the family size as a consequence of the 2 child policy introduced in 1972 [41]. However, 
the post 65 year age category sees a drastic difference in incidence rates among the three 
ethnic groups (Figure 2.3b). The incidence rates for the Chinese remained constant after 
the age of 65 years, for the Indians, increased and for the Malays, decreased [5]. These 
differences can possibly be explained by the ethnic differences in the exposure to certain 
risk factors or the ethnic difference in the response to similar changes to risk factors or 
both [5]. Obesity, with possibly limited effect on fertility among postmenopausal Indian 
women (known risk factor for breast cancer) could have led to the increasing rates of 
breast cancer in the elderly [5]. 
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Figure 2.1 Age standardized incidence rates for selected cancer sites in Singaporean 
females from 1968 to 2007 
 
Source: Singapore Cancer Registry report no. 7 
(http://www.nrdo.gov.sg/uploadedFiles/NRDO/Publications/inc_report_v8%281%29.pdf) 
Figure 2.2 Age-specific incidence rates for breast cancer. Singapore 2003–2007. 
 






Incidence rates of breast cancer in Malaysia are lower than those seen in Singapore [35]  
and roughly one in every twenty women will develop the disease during their lifetime. 
The median age of disease onset in Malaysia is 50 years [1] and like Singapore, the 
median age of onset of the disease in Malaysia is lower than that seen in developed 
countries [35]. Figure 2.4 shows a comparison of age specific incidence rates for 
Malaysian, Singaporean and South Australian female breast cancer patients. Patients 
from Singapore and Malaysia follow a similar trend with an initial rise in breast cancer 
incidence rate up to the age of 45-50 years after which a dip is seen whereas patients 
from South Australia tend to follow the western pattern with increasing incidence rates 
with increasing age. Possible explanations for this trend could be the increased use of 
Hormone Replacement Therapy (HRT) among post menopausal women in developed 
countries which is a known risk factor for breast cancer. HRT use is not prevalent in 
Singapore and Malaysia. This could also be due to a ―cohort effect‖ where succeeding 
generations of women are exposed to differing risk factors; the generation of women born 
after the Second World War has successively higher risk of developing breast cancer than 
previous generations.  
The breast cancer IR and MR (per 100,000) for all SEA countries, in 2008, was 31.0 and 
13.4 respectively (Table2.1b). Breast cancer IR in other SEA countries such as Brunei, 
Laos, Cambodia, Thailand and Indonesia are lower compared to Western countries 
(Table 2.1b)[42] but breast cancer is still the most common cancer among women in 
these countries [43, 44] . Among all SEA countries, the highest IRs were seen in 
Singapore while the lowest rates were seen in Vietnam (Figure 2.5). Mortality rates per 
100,000 were the highest in Indonesia (18.6) (Table 2.1b). A study looking at time trends 
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in breast cancer incidence rates showed an increase in truncated age standardized IR from 
the first 5 year period (1993 to 1997) to the next 5 year period (1998-2002) for SEA 
countries like Singapore, Thailand and Philippines (Figure 2.6) [45]. 
 
Figure 2.3 Overall age specific breast cancer rates in Singapore stratified by ethnicity 
from 1968-2002. 
 
Source: Ethnic differences in the time trend of female breast cancer incidence: Singapore, 







Figure 2.4 Age dependent incidence of breast cancer  
 
Source: Epidemiology of Breast Cancer in Malaysia. Yip et al (2006) 
 
 
Figure 2.5 Estimated age specific incidence rates (per 100,000 female population) for 




Source: The burden of cancer in member countries of the Association of South East 
Asian Nations (ASEAN). Kimman M et al. (2010) 
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Figure 2.6: Trends in invasive breast cancer incidence during 1993-2002 by country. 
 
Source: Recent trends and patterns in breast cancer incidence among Eastern and 
Southeastern Asian women. Shin et al. (2010) 
 
With rising incidence of breast cancer in SEA [5, 45], improving breast cancer healthcare 
in the region remains a priority. This may be addressed by increasing disease awareness, 
implementing rigid screening programs and increasing funding to improve the quality of 
life and prolong survival of the patients. 
 
Screening for breast cancer 
Screening is the identification of individuals within an asymptomatic population who 
have (or who are likely to develop) a specified disease, at a time when intervention may 
result in improvement of the prognosis of the disease. In the case of breast cancer, the 
intervention can be in the form of surgery, radiotherapy or chemotherapy. Screening can 
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be in the form of a self breast examination, a clinical breast examination or the use of 
imaging techniques such as mammography or ultrasound. 
Screening allows for early detection, thus bringing forward the time of diagnosis and 
improving the prognosis of breast cancer. 
Clinical examination 
Clinical breast examination (CBE) aims at detecting breast abnormalities in order to find 
palpable breast cancers at an early stage of progression. Although CBE detects some 
cancers that are missed by mammography, the magnitude of its contribution to early 
detection is small [46]. For women who have not been recommended mammography as 
they are either under the age of 40 years or are not subjected to mammography as per 
guidelines, CBE may play an important role in early detection [47]. CBE encompasses 
the clinical history, visual inspection, palpation as well as reporting and interpretation of 
symptoms. Barton et. al. pooled data from 6 studies and obtained an overall estimate of  
54.1%  sensitivity and  94.0% specificity for CBE [48]. As regards survival, physicians 
can detect lumps as small as 3.0 mm which is well within the size range for which a 
survival advantage has been reported [49]. 
A few trials have evaluated the mortality reduction associated with CBE but none of 
these studies showed effective reduction in mortality associated with CBE [50, 51]. No 
trial comparing CBE with mammography has been conducted to date and the fact that 
mammography screening reduces breast cancer mortality makes it even less likely that 





Mammographic screening (an x-ray of the breast) has been introduced in many parts of 
the world, targeting women aged 50 years and above, and this has led to an increased 
detection of early breast cancers resulting in inflated incidence rates [53] including 
Singapore [54]. Screening is said to reduce mortality in Singapore by up to 25%. 
However, there is considerable debate as to whether screening truly decreases mortality, 
especially in developed countries and whether it is truly beneficial to women with breast 
cancer (Table 2.2). 
Table 2.2 Estimated benefits and harms associated with 10 year course of screening 
mammography for 2500 women who are 50 years of age*. 
Benefit 
One woman will avoid 
dying from breast 
cancer. 
Harm 
Upto 1000 women will have at least one ―false alarm‖ about 
half of who will undergo biopsy. 
Breast cancer will be over diagnosed in 5 to 15 women, who 
will be treated needlessly with surgery, radiation, 
chemotherapy or a combination. 
* The assumed benefit of screening mammography is a reduction of 10% in the rate of 
death from breast cancer. 
Source: Screening Mammography- A Long Run for a Short Slide? Gilbert Welch. (2010) 
 
The Singapore Breast Screening Project (1993-1996) led to an increase in the detection 
rate of ductal carcinomas in situ [36]. The Singapore Cancer Registry data showed that 
there had been a shift in the age of peak incidence of breast cancer from 45-49 years in 
1993-1997 to 50-55 years in 1998-1999. This, coupled with the fact that Singapore is 
increasingly following the Western lifestyle pattern (later age at first birth, lesser number 
of children, shorter duration of breast feeding, increased alcohol and smoking 
consumption, decreased physical activity), led the Government of Singapore to introduce 
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the first population based screening program in Asia called BreastScreen Singapore in 
2002 [36]. This program targeted women aged 50 to 69 years with the aim being to 
reduce the mortality by 10% by the year 2010 [55]. 
Results from eight randomized controlled trials across various geographic regions  
showed that mammography decreased mortality by 25-30% among breast cancer patients 
and though this was debated by many researchers, the general consensus is that the 
efficacy of mammography in reducing mortality holds true [56-58]. 
Mammography can detect tumors that are not detectable by clinical breast examination; 
such tumors generally have a good prognosis and can even be cured by appropriate 
treatment [56]. A major drawback of mammography is that a majority of the women 
presenting with abnormal mammograms do not have breast cancer leading to an increase 
in the number of false positives thereby inflating incidence rates [59, 60]. For many years 
there has been a debate regarding screening mammography of women in their 40s [61]. 
The effect of screening in younger women is slower to appear than women aged above 50 
years. This is probably due to mammographically denser breasts in younger women 
resulting in reduced sensitivity of the mammography [62]. The 15 year mortality from 
breast cancer among women in their 40s decreased by about 20% as a result of screening 
[63, 64].  
Elderly patients are not entered in clinical trials for mammography. A case control study 
conducted in The Netherlands showed that mammographic screening among women aged 
65 to 74 led to a 55% decrease in mortality from breast cancer, however, the reduction in 
risk was boarderline significant [RR = 0.45 (95%CI, 0.20  to 1.02) [65]. This study does 
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however suggest that mammography could result in a mortality reduction among elderly 
women. 
Ultrasound has an established role in the further evaluation of clinical and 
mammographic breast abnormalities at all ages and is the imaging method of first choice 
for the assessment of symptomatic breast lesions in younger women (< 35 yearsof age) 
[66]. It is reliable in distinguishing cystic from solid lesions and recent improvements in 
ultrasound resolution and advances in colour Doppler technology have meant that benign 
and malignant lesions can be identified with some degree of confidence, particularly 
when used in conjunction with clinical and mammographic assessment [66]. 
Ultrasound is used either separately to screen women with high familial risk [67] or in 
conjunction with mammography to detect cancer among women with highly dense breast 
tissue [68]. Up until the early 1990‘s ultrasound was mainly used to distinguish solid 
breast masses from cysts [68, 69] but more recently, its diagnostic potential has 
improved.  
Magnetic Resonance Imaging (MRI) as a preoperative diagnostic tool has gained 
importance over the last decade due to its high sensitivity to detect occult breast cancer in 
both the affected as well as the contralateral breast [70]. 
MRI has been documented to be a superior diagnostic tool for those women with a high  
risk of breast cancer in several studies [71, 72]. From the mid to the late 1990‘s there 
were at least 6 prospective studies carried out in the The Netherlands, UK, Canada, 
Germany, US and Italy to compare the efficacy of MRI to mammography and to gauge 
the additional benefit MRI gave to women having undergone mammography. These 
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studies reported a greater sensitivity of MRI compared to mammography or any other 
imaging tool.  
Table 2.3 shows the differences in specificity and sensitivity between the three major 
imaging tools namely mammography, ultrasound and MRI for the six major studies 
published to date. These studies looked at differences between diagnostic tools to detect 
breast cancer in high risk individuals. 
 








Centres (n) 6 1 22 1 13 9 
 Women (n) 1909 236 649 529 390 105 
Age Range (yrs) 25-70 25-65 35-49 >= 30 >=25 >= 25 
Cancers (n) 50 22 35 43 4 8 
Sensitivity %       
MRI 80 77 77 91 100 100 
Mammogram 33 36 40 33 25 16 
Ultrasound n/a 33 n/a 40 n/a 16 
Specificity %       
MRI 90 95 81 97 95 99 
Mammogram 95 >99 93 97 98 0 
Ultrasound n/a 96 n/a 91 n/a 0 
Source: American Cancer Society Guidelines for Breast Screening with MRI as an 
Adjunct to Mammography. Saslow D et al (2007).  
 
Clinical investigation of breast cancer  
For all suspected breast cancer patients a general approach to diagnose or rule out  breast 
cancer has been formalized and is called ―triple assessment‖. Triple assessment is the 
triad of clinical sign and symptoms ( clinical examination), imaging ( Mammography and 
Ultrasound) and histologic confirmation (needle biopsy). Triple assessment ensures that 
an accurate diagnosis of the suspected lump is arrived at so as to decrease the chance of 
missing out the cancer. 
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 Clinical examination and Imaging were discussed in detail under the heading ―Screening 
for breast cancer‖ 
Breast Biopsy 
Breast biopsy is performed once a suspicious breast finding is detected either clinically or 
by imaging. Though lumps are detected with the help of imaging tools, it is not possible 
to tell from these imaging tests whether the growth is benign or malignant. Hence a 
biopsy is performed. A common procedure is to conduct a core needle biopsy using 
stereotactic or ultrasonographic guidance or perform fine needle aspiration cytology 
(FNAC). However, for lesions that are later proven to be cancerous, the core biopsy has 
the advantage of providing a greater quantity of sample for histological diagnosis, 
receptor information and is thus used as an additional test  before the patient is subject to 
surgery [73, 74].  
Triple assessment aims at minimizing false positive as well as false negative findings 
thereby reducing morbidity. If a cancer is detected early, more effective treatment can be 
implemented resulting in improved quality of life as well as improved disease free 
survival. 
Patient demographics and tumor characterization  
Determining patient sociodemographic information helps in predicting whether the 
patient will have a recurrence and in predicting survival of the patient. Age, ethnicity, 
socioeconomic status, family history, education are important predictors of breast cancer 
incidence. Several studies in the West have shown that breast cancer survival is poorer in 
developing countries and among women with low socioeconomic status (SES) [3, 75-78]. 
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Women with a higher educational level also had better survival as compared to those with 
a lower education background [79]. Some studies suggest that patients with a family 
history of breast cancer had a better survival probability as compared to those without 
any family history [80] which may be due to increased awareness about the disease and 
various treatment options. 
Some patients have indolent disease which can be dealt with using only local therapy 
while some have a more aggressive and often fatal systemic disease. It is important to 
identify patients with indolent and low risk tumors to avoid medically unnecessary and 
potentially harmful interventions. 
Tumors can be either malignant or benign. Breast lesions are believed to progress in a 
linear pattern from ductal hyperplasia without atypia to atypical ductal hyperplasia and 
then to ductal carcinoma insitu and invasive cancer [81]. A benign lesion progresses to a 
malignant one as the number of genetic mutations increases. Several studies have shown 
that during this transformation, the levels of estrogen receptor alpha and HER2/NEU 
receptor levels increase [82]. 
Tumors can be characterized by size, grade, and receptor status. For patients with 
invasive  breast cancer, tumor size has been recognized as an important predictor of 
survival [83, 84]. Tumor size is also an important predictor of treatment and is a vital 
piece of information when it comes to staging of breast cancer patients. 
Tumors are assigned grades based on microscopically detected abnormalities and 
depending on how quickly the tumor is likely to grow and spread. Tumor grade, also 
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called differentiation, refers to how much tumor cells resemble normal cells of the same 
tissue type. 
The majority of tumor grading systems used for breast cancer combine scores for nuclear 
grade, tubule formation and mitotic rate. The grading of a cancer in the breast depends on 
the microscopic similarity of breast cancer cells to normal breast tissue, and classifies the 
cancer as well differentiated (low grade or grade 1), moderately differentiated 
(intermediate grade or grade 2), or poorly differentiated (high grade or grade 3), 
reflecting progressively less normal appearing cells that have a worsening prognosis.. 
The cumulative score for all three elements gives the ―grade‖ for that tumor [85, 86]. The 
most popular grading system for breast cancer is the Elston-Ellis modification of the 
Scarff-Bloom-Richardson grading system [87, 88] and is called the Nottingham grading 
system.  
Receptor implication in breast tumor cells is an important prognostic indicator and, more 
importantly a predictive marker for receipt of anti-hormonal therapy or targetted therapy 
[89]. There are two major steroid receptors implicated in breast cancer namely the 
estrogen receptor (ER), progesterone receptor (PR).The human epidermal growth factor 
receptor (HER2/NEU) is also implicated in certain breast cancer patients. 
Estrogen receptor‘s implication in breast cancer was  detected as early as 1896 by 
Beatson [90]. The alpha subtype of the ER as well as ER regulated PR are of special 
interest as their protein levels are elevated in premalignant and malignant breast lesions 
as opposed to normal tissue. Furthermore, both receptors are valuable predictive and 
prognostic indicators of breast cancer [91] and blockade of ER alpha has become one of 
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the major pathways for treating and controlling the disease [92]. Anti estrogens are now 
used successfully to inhibit ER mediated activation of gene transcription. HER2/NEU 
receptor is also a therapeutically and prognostically important factor for breast cancer 
[93] and unlike the hormone receptors, it is a tyrosine kinase receptor. Structurally it is 
closely related to the epidermal growth factor receptor and its overexpression acts as a 
predictive marker for tumor agressiveness and responsiveness to therapy [94]. 
HER2/NEU protein overexpression has been associated with a higher recurrence risk for 
both node positive and node negative breast cancers [95]. 
Treatment of breast cancer 
The three major modes of treatments for breast cancer are surgery, chemotherapy 
including anti-hormonal therapy and radiotherapy. No one treatment fits every patient 
and usually a combination of two or more is required. Treatment heavily depends upon 
the age, stage, tumor characteristics, comorbidities and hormonal receptor status of the 
patient [96]. 
Limited data is available on the differences in the treatment modalities for native Asian 
patients and whether different modalities of treatment are practiced or available in SE 
Asian countries [1]. Clinical trials on newer chemotherapeutic agents are not extensively 
carried out in the Asia-Pacific region and thus clinical experience with existing treatment 
in the Asia–Pacific region is limited and variable [97]. Studies carried out in the West 
suggest that Asian American women were more likely to undergo mastectomy as 
compared to White American women [98] and that Chinese women were less likely to 




Surgery has always been the primary mode of treatment for breast cancer and is so today. 
Surgery is indicated for operable disease only. Surgery for breast cancer has drastically 
improved from deforming ablative procedures to procedures that not only preserve the 
breast but also the axillary anatomy of the patients [100, 101]. Mastectomy, i.e., the 
complete removal of the breast is required for women with extensive or multi-centric 
disease for whom breast conservation is inappropriate. Women undergoing mastectomy 
for early stage breast cancer as well as those undergoing risk reduction (prophylactic) 
mastectomy generally do not require adjuvant radiotherapy and are good candidates for 
immediate breast reconstruction [101]. Many women opt for bilateral mastectomy with 
immediate breast reconstruction as their preferred method for dealing with high lifetime 
risk of developing the disease with uptake rates for surgery of 43% and 32% respectively 
for BRCA1 and BRCA2 gene mutation carriers [102].   
Tumorectomy or breast-conserving surgery involves the removal of the affected portion 
of the breast thereby conserving the breast. Breast conserving surgery has become the 
standard treatment for early stage breast cancer [103, 104]. The administration of 
radiotherapy following breast conserving surgery decreases both the risk of ipsilateral 
breast cancer [105, 106] as well as breast cancer specific mortality [107] . This 
combination is still preferred by most surgeons provided tumor size and grade are within 
limits for breast conserving surgery [108]. The outcome of patients who have undergone 
breast conserving surgery has been improving and the risk of local recurrence in such 
patients is now less than  that reported in initial clinical studies [109]. 
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As part of the surgical treatment, a sentinel lymph node (SLN) (first lymph node to drain 
lymph from the breast) biopsy may be performed either independent or in conjugation 
with an axillary clearance. The technique of SLN biopsy, introduced in the mid 1990s to 
detect lymph node metastases [110], was developed to provide surgeons with enough 
information to avoid axillary dissection provided the sentinel node is negative [111]. 
Some studies suggest that the need for axillary dissection following a positive sentinel 
node biopsy may be over rated and could lead to increased morbidity [112, 113]. There is 
however the possibility of false negative results for the sentinel node biopsy and thus the 
surgeon should also consider other indicators for distant metastases such as tumor 
receptor status, poor tumor cell differentiation and over expression of HER2/NEU 
receptors before omitting an axillary dissection [114]. Axillary dissection is the surgical 
procedure in which an incision is made in the armpit (axilla) region to identify, examine 
and/or remove lymph nodes. Adequate lymph node dissection requires the removal of at 
least 10 LN [115]. Proponents of the axillary lymph node dissection (ALND)  note that 
about 50% of breast cancer patients will have a non-sentinel axillary lymph node 
metastasis [116, 117] suggesting that an (ALND)  could provide additional prognostic 
information and could decrease axillary recurrence [110]. However, another study 
conducted by Giuliano et al suggested that among patients with limited SLN metastatic 
breast cancer treated with breast conservation and systemic therapy, the use of SLN 
dissection alone compared with ALN dissection did not result in inferior survival [118]. 
Chemotherapy and hormone therapy  
Surgery alone is usually not sufficient to optimally manage breast cancer. Systemic 
treatment, that is the administration of chemotherapeutic agents, can be done after 
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(adjuvant therapy) or before (neoadjuvant therapy) surgery depending on the grade, 
tumor size, stage, and age of the patient. Adjuvant therapy has had a major effect in 
prolonging both disease free and overall survival [119]. Another form of adjuvant 
treatment is beneficial to selective patients based on tumor characteristics (targeted 
therapy) for example, the administration of adjuvant tamoxifen (an ER modulator) to ER 
positive breast cancer patients has shown to improve their 15 year survival rate by 31%, 
but it does not benefit women with estrogen receptor negative disease [120]. 
Trastuzumab, a monoclonal antibody used for targeted therapy, when administered as an 
adjuvant to surgery, showed an improvement of almost 50% in disease free survival in 
15% to 20% of the patients over expressing the HER2/NEU receptor [121, 122]. In 
addition to these targeted approaches, adjuvant chemotherapy in the form of alkylating 
agents, antimetabolites, anthracyclines and taxanes in various combinations has 
contributed to the overall improvement of patients with operable breast cancer.  
Neoadjuvant (also known as primary or induction) chemotherapy or Neoadjuvant  
endocrine therapy, that is the administration of chemotherapeutic agents prior to surgery. 
Neoadjuvant chemotherapy is administered to allow breast conservation or to downsize 
the locally advanced cancer or both. When administered for locally advanced disease, the 
main aim is to downsize the tumor so that it reaches an operable size. The National 
Surgical Adjuvant Breast and Bowel Project (NSABP) B-18 trial showed that the 
administration of neoadjuvant chemotherapy resulted in high rates of tumor response 




Radiotherapy is an equally important mode of treatment for breast cancer and is 
mandatory post breast conserving surgery [120, 124]. It is commonly administered in 
fractions 2 Grays/day with a total of 50 Gray [125]. 
Prognostic indicators of breast cancer 
Prognosis is a medical term for predicting the likely outcome of an illness and a factor 
that predicts this outcome is a prognostic indicator. In an ideal world, once a malignant 
disease is detected, treatment is administered to effect a cure [126]. If a cure is not 
possible, an estimate regarding recurrence or more importantly death is made. These 
estimates are most often derived from information provided by pathology reports, 
conveniently translated into a numerical index and are termed prognostic 
estimates.Prognostic factors are important for forecasting outcomes in individual patients 
and can be used by the clinicians to alter or adjust treatment options. One of the most 
important parameters to define risk categories for breast cancer specific death in early 
breast cancer patients is the nodal status (positive or negative) [127]. By assigning a risk 
category to every patient, appropriate prognostic predictions can be made. Table 2.4 
gives the three risk categories into which patients can be classified depending on their 
nodal status as well as tumor characteristics [128]. 
Many variables have been shown to correlate with the prognosis of patients with breast 
cancer. Among the most useful are the number of positive lymph nodes, tumor size and 
histological grade. The Nottingham Prognostic Index (NPI) combines these three 
prognostic factors to give a score/index for each patient. This index was developed in 
1982 based on a retrospective analysis of  9 factors (of which only the above 3 mentioned 
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were significant) in 387 patients [129, 130].  The higher the index for a patient , the 
worse the prognosis. 
 
Table 2.4 Categorization of patients with operable breast cancer into risk categories 
based on tumor characteristics. 
















      Node negative plus all of the following: 
 Pathological tumor size ≤ 2 cm 
 Tumor grade 1 
 No peritumoral vascular invasion 
 HER2/neugene neither over expressed nor amplified 
 Patient age ≥35 years 
 
       Node negative plus at least one of the following 
 Pathologic tumor size > 2cm 
 Tumor grade 2-3 
 Peritumoral vascular invasion 
 Confirmed HER2/neu gene over expression or amplification 
 Patient age <35 years 
 
Node positive (1-3nodes)  plus 
 Confirmed HER2/neu gene over expression or amplification 
Node positive (≥4 nodes) 
Source: Meeting Highlights: International Expert Consensus on the Primary Therapy of 
Early Breast Cancer. Goldhirsch et al. (2005) 
 
The NPI is calculated as follows: 
Nottingham Prognostic Index (NPI) =0.2 (Size  in cm) + LN involvement (lymph node, 
1-3 bylevel) + Grade (1-3: good, moderate, poor) [each factor is weighted according to 
regression coefficients of a Cox Proportional Hazards analysis and calculated for each 
patient] 
LN involvement: 0 =1, 1-3 = 2, >3 = 3 
Grade: Grade I =1, Grade II =2, Grade III =3 
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The NPI has been validated by further studies in Nottingham and by studies from several 
other countries [131, 132]. When combined with predictive factors (estrogen and 
HER2/NEU receptor status), patients‘ personal preferences and menopausal status, the 
NPI is a useful tool which gives advice to clinicians regarding the choice of adjuvant 
systemic treatment to be administered [133]. One of the advantages of the NPI is its 
simplicity and though studies have shown that inclusion of other factors such as 
HER2/NEU status, vascular invasion and basal phenotype could improve the prognostic 
value of the NPI, validation for such inclusions will be needed [133]. 
Adjuvant! Online for Breast Cancer is a free web-based prognostication tool which was 
developed based on the Surveillance, Epidemiology and End Results (SEER) database 
and treatment efficacy data from meta-analyses [134]. It estimates individual ten year 
survival probabilities, and risks of relapse in patients with breast cancer, based on clinical 
characteristics and systemic treatment. In addition, Adjuvant! Online helps to predict the 
absolute benefit of adjuvant therapy in individual patients.  
Since its introduction in early 2000s, Adjuvant! Online has gained worldwide recognition 
amongst clinicians as a tool to aid patient counselling and clinical decision making in the 
management of women with early breast cancer [135]. The program has been validated 
by several groups in Canada and Europe [135, 136]. Two studies have shown that the 
model accurately predicts survival probabilities across most patient groups [135, 137], 
whereas the study conducted in United Kingdom found that Adjuvant! Online 
systematically overestimated survival by about 5.5 percent [138]. 
In South East Asia, Adjuvant! Online predicted 10 year survival (70.3%) was 
significantly higher than the observed 10 years survival for Malaysian breast cancer 
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patients (63.6 %, difference of 6.7%; 95%CI: 3.0- 10.4%) [139]. The model was 
especially overoptimistic in women under 40 years and in women of Malay ethnicity, 
where survival was overestimated by approximately 20% (95%CI: 9.8-29.8%) and 15% 
(95%CI: 5.3-24.5%) respectively [139].  
Lymph node ratio 
The most accurate of prognostic indicators to date is the pathological nodal staging 
system. It categorises patients depending upon the number of axillary lymph nodes 
involved. The classification is as follows: 
N0 : 0 lymph nodes affected 
N1 : 1 to 3 lymph nodes affected  
N2 : 4 to 9 lymph nodes affected 
N3 : >= 10 lymph nodes affected 
It has been noted that patients classified as N3 are at a survival disadvantage and should 
be given aggressive therapy [140]. A major limitation to this prognostic indicator is the 
fact that the number of positive nodes identified is dependent on the number of nodes 
excised. The process of axillary dissection that determines the number of positive nodes 
varies across institutions as well as across surgeons from the same institution. The 
pathological nodal staging system also depends heavily on the pathologists‘ experience 
which also varies across institutions. Hence Vinh-Hung et al, taking the above into 
account, proposed an alternative to the current pN staging system called the ―lymph node 
ratio (LNR)‖ [22, 23, 141]. Although the LNR hasn‘t yet been accepted as an alternative 
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or supplement to the current pathological nodal staging system, preliminary studies show 
that it is as good (if not better) a prognostic indicator for breast cancer patients [24, 25, 
142, 143]. 
The LNR is calculated as follows: 
Lymph node ratio = number of positive axillary nodes / total number of nodes excised 
Being a ratio, it did not take into account the number of lymph nodes excised alone, nor 
did it require the mode of treatment to predict survival [22]. The LNR could be viewed as 
a per patient standardization in which the number of involved nodes is standardized to the 
number of nodes removed [141].  Figure 2.7shows the survival curves for the 1829 
patients from the Geneva Cancer Registry stratified by pN staging (N1, N2 and N3) as 
well as by   LNR (0.01-0.2, 0.2-0.65, 0.65-1) each category corresponding to low, 
intermediate and high risk of breast cancer specific death [22]. The researchers noted that 
the breast cancer specific survival curves for the intermediate and high risk groups, 
stratified by pN stage, crossed after 15 years of follow up whereas no such crossing of 
survival curves was seen when the patients were categorized based on their lymph node 
status. This indicated that the LNR could possibly be a better prognostic indicator for 
breast cancer specific survival in this setting [22]. Their conclusions were further fortified 
by the results from the multivariate Cox Regression analysis (Table 2.5) which showed 
an overlapping confidence interval for the breast cancer specific hazard ratios for the N2 
and N3 categorized patients. No such overlap was seen for the intermediate and high risk 
patients stratified by LNR. 
 
A study from Korea showed no overall difference between LNR and pN staging in 
categorizing poor, intermediate and good survivors, except for certain subgroups, i.e. 
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women aged <35 years, HER2 over expressing and triple negative tumors[26]. Other 
studies conducted in different populations also suggested that LNR was a significant and 
independent predictor of outcome for breast cancer patients [10, 23-25, 142] 
 
Table 2.5 Effect of LNR and pN classification on breast cancer mortality among patients 
with lymph node-positive breast cancer. 
Variable Hazard Ratio* 95% CI P 
Lymph node ratio 
Low, ≤ 0.20 








1.46 to 2.18 












1.69 to 2.53 
2.23 to 3.61 
<0.001 
* Cox proportional hazards model; only deaths from breast cancer are considered. Hazard 
ratios are adjusted for age, year of diagnosis, socioeconomic class, tumor location, histologic 
grade, tumor size, radiotherapy, chemotherapy and endocrine therapy. 
Source: Lymph Node Ratio as an alternative to pN staging in Node Positive Breast 
Cancer. Vinh-Hung et al. (2009) 
 
Figure 2.7 Kaplan Meier survival curves according to risk groups. (A) risk groups 
defined by pN. (B) risk groups defined by lymph node ratio (LNR). 
 
Source: Lymph Node Ratio as an alternative to pN staging in Node Positive Breast 




Lymph node ratio is rapidly gaining importance as a prognostic indicator for breast 
cancer. Validation studies in different settings are still required before a firm conclusion 
about the informativeness of the LNR is made. 
 
Survival of breast cancer patients 
Breast cancer is the most prevalent cancer in the world today due toits high incidence and 
reatively good prognosis[144]. Improved treatment and early detection has increased 
breast cancer survival to such an extent that previously rising mortality rates have been 
on the decline for the past 15 years in most Westernized countries[27, 28].  Figure 
2.8shows us the age standardized incidence and mortality rates for breast cancer stratified 
by geographic regions of the world.  
It is seen that mortality rates fluctuate to a lesser extent than incidence rates with lower 
mortality rates in developing countries as compared to the more affluent ones. The 
favourable survival of breast cancer cases in Western countries (89% in five years in 
cases registered in the SEER program from 1995-2000) can be attributed to screening 
[144].Today, more than half of incident cases occur in the developing world. Combined 
with still high case-fatality rates, this means that mortality from breast cancer is a leading 
cause of death among women in developing countries [145]. The high probability of 
dying from breast cancer—the case fatality rate, which is approximated by the ratio of 
mortality to income—across the developing world further reflects the inequities in early 
detection and access to treatment. The number of deaths as a percentage of incident cases 
in 2008 was 48% in low-income, 40% in low middle-income, and 38% in high-middle-
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income countries, while it was 24% in high-income countries according to the most 
recent Globocan/IARC data [145]. 
Singaporean women diagnosed between  1980-1999 experienced an overall poorer 
survival than their European counterparts [39]. In our analysis we noted that there were 
differences in overall survival rates for women diagnosed in Singapore or Malaysia when 
stratified by the three major ethnic groups, Chinese, Malay and Indian with Malays 
having a lower overall 5 and 10 year survival than the other two ethnicities. 
 
The overall 5-year survival from breast cancer in Malaysia correlatedwell with the 
average of 57% in developing countries [35]. Looking at survival according to stage at 
diagnosis, it was clear that early diagnosis is associated with a better survival. The 
survival of 81.7% in Stage 1 disease could be further improved by improved treatment, as 
it is now possible to obtain a survival of 90% or more[35]. If survival is mainly 
dependent on early diagnosis and treatment, these are clearly the areas that we need to 

















Figure 2.8 Age standardized incidence and mortality rates for breast cancer aroung the 
world 
 
Source: Global Cancer Statistics,2008. Jemal A et al (2011) 
 
Ethnicity amd survival of SE Asian breast cancer patients 
Malaysia and Singapore are multiethnic South East Asian nations comprising 3 major 
ethnic groups i.e. Malays, Chinese and Indians [146, 147]. In these populations, age-
standardized incidence rates (ASRs - world standardized) of breast cancer differ 
substantially, whereby the rate is highest among the Chinese (Malaysia: 59.7 per 10
5
, 





Singapore: 45.8 per 105 person-years) and the Malays (Malaysia: 33.9 per 10
5
, 
Singapore: 44.8 per 105 person-years) [146, 147]. Results from the SMBCWG rsearch 
showed that the five year overall survival was not significantly different between the 
Chinese (72.4%; 95%CI: 70.4%-74.4%) and Indian (65.3%; 95%CI: 59.4%-71.1%) 
patients, but was substantially lower in Malay patients (47.4%; 95%CI:42.7%-
52.1%)[148]. Compared to the Chinese, Malay ethnicity was associated with 60% higher 
risk of all cause mortality (HR: 1.60; 95%CI: 1.44-1.77), independent of patient profile, 
TNM stage, tumor characteristics and treatment [148]. Indian ethnicity was also 
associated with a modest increase in mortality risk (HR: 1.16; 95%CI: 1.03-1.32)[148]. 
Treatment and survival of breast cancer 
Effective treatment has been shown to improve overall survival of breast cancer patients. 
When treatment and its effect on survival is studied, there is an underlying assumption 
that improved overall response rates would translate into long term survival benefits 
[149]. 
In a population based analysis of overall survival conducted in British Columbia, the 
introduction of new agents over the last ten years such as taxanes, aromatase inhibitors, 
and trastuzumab was associated significantly with improvement in overall survival time  
across the population [150]. 
In addition to this , a number of randomized clinical trials have been conducted and have 
reported a statistically significant  survival imporvement in women with metastatic breast 
cancer [151-154].  
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Surgery is the main mode of treatment for breast cancer. In a population based study 
using patient data from the Geneva Cancer Registry, Verkooijen et al observed that 
women refusing surgery for various reasons had a poorer breast cancer specific survival 
than those patients who didn‘t refuse surgery (Figure 2.9). 
This is reported to be the first study to look at the impact of lack of surgery on breast 
cancer specific survival with women refusing surgery being at a two fold increased risk 
of breast cancer specific death even after adjusting for stage, tumor characteristics and 
non surgical treatment [155]. 
Figure 2.9 Observed breast cancer specific survival of breast cancer patients in relation 
to receipt of primary surgery of the breast. 
 
Source: Patients‘ Refusal of Surgery Strongly ImpairsBreast Cancer Survival. Verkooijen 
et al. (2005). 
 
Relative survival 
Relative survival is defined as the ratio of the proportion of observed survivors in  
cohort of cancer patients to the proportion of expected survivors in the background 
population with same age and period distribution[156].Relative survival is described in 
detail in chapter 3. 
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Table 2.6 gives the 5 year relative survival estimates of women diagnosed with breast 
cancer between 1990 to 1994 in various geographic locations in Europe. 
Table 2.6 Age standardized relative survival (%) for breast cancer 5 years after diagnosis 
for women diagnosed between 1990-1994.  
 Relative survival (%)   Relative survival (%) 
 female   female 
Austria 75.4  Norway 77.2 
CZ 64.0  Poland 63.1 
Denmark 74.9  Portugal 71.9 
Estonia 61.9  Slovakia 59.5 
Finland 81.4  Slovenia 67.4 
France 81.3  Spain 78.0 
Germany 75.4  Sweden 82.6 
Iceland 79.6  Switzerland 80.0 
Italy 80.6  UK - England 73.6 
Malta 74.8  UK - Scotland 72.3 
Netherlands 78.2  UK - Wales 69.5 
CZ: Czech Republic, UK: United Kingdom 
Source:EUROCARE-3: survival of cancer patients diagnosed 1990–94—results and 
commentary. Sant et al. (2003). 
 
Limited data is available on relative survival estimates for breast cancer patients from 
South East Asia. A study conducted by the International Agency for Research on Cancer 
(IARC) showed that the age standardized RSRs for breast cancer patients from 
Philippines and Thailand were significantly lower than those of the US white patients for 
the period of 1974 to 1991 [157]. 
Long term relative survival rates like 5 and 10 year estimates should be interpretted with 
some caution as patients from different periods of diagnosis could have been subject to 
different treatment and diagnostic procedures [158] and the predominance of one such 




 This thesis focusses on the clinical outcomes of breast cancer among female breast 
cancer patients from Singapore and Malaysia and special attention is paid to the progosis 
of the patients. We alsoestimate the prognostic value of the axillary lymph node ratio 
among Singaporean and Malaysian breast cancer patients and study the impact of older 
age on presentation and management of breast cancer patients from Singapore.  The data 
for these studies were obtained from the Singapore Malaysia Breast Cancer Working 












Chapter 3 Epidemiology concepts and statistical methods used 
for analysis 
This chapter highlights the key epidemiology concepts that were taken into consideration 
while analysing the data as well as the statistical tests used during analysis throughout the 
thesis. 
Confounding 
A confounder is an extraneous variable that correlates with both the dependent and 
independent variable. A problem posed in many epidemiology studies is that we observe 
a true association and are tempted to derive a causal inference, when in fact, the 
relationship may not be causal. This is due to the effect of the coufounding variable. 
Ways to deal with confounding include: 
1) Stratified analysis 
2) Matching cases and controls for the potential confounding factor 
3) Adjusting for the confounding factor during data analysis. 
4) Exclusion of those data points with the confounding factor. 
Example from this thesis: Stage is a strong confounder in the association between ―place 
of diagnosis (Singapore or Malaysia)‖ and all cause mortality. One way to account for 
this is to adjust for stage in the multivariate Cox Regression analysis to determine the true 




Confounding by Indication 
Evaluating treatment effects from observational data is problematic. Prognostic factors 
may influence treatment decisions, producing a type of bias referred to as "confounding 
by indication"[159]. Controlling for known prognostic factors may reduce this problem, 
but it is always possible that a forgotten or unknown factor was not included or that 
factors interact complexly. Confounding by indication has been described as the most 
important limitation of observational studies of treatment effects.  
Example from the thesis: In our study comparing survival between elderly and young 
Singaporean patients, elderly patients presented with more severe disease characteristics, 
and as a result, could have received less appropriate treatment. However, this 
confounding by indication did not seem to affect the association between ―age‖ and ―all 
cause mortality‖. This is because, even though large survival differences were observed 
between old and young patients overall, on stage stratification, the survival differences 
were substantially reduced. Further, type of treatment, after adjusting for disease 
characteristics, did not influence survival in the elderly, but did so for the young patients. 
Bias 
Bias is any systematic error in the design, conduct or analysis of a study that results in a 
mistaken estimate of an exposure‘s effect on the outcome. The two major biases 
encountered in epidemiology studies are slecetion bias and information bias. When the 
way in which cases and controls or exposed and non exposed individuals are selected 
such that an association between the exposure and outcome is seen, and if , in reality, no 
such association exists, then the apparent association is a result of selection bias. The 
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nature of this selection potentially affects the generalizability of the  study. Information 
bias can occur when the means for obtaining the information from a study subject are 
inadequate as a result, some of the information obtained regarding the exposure and/or 
outcome is incorrect. This could lead to misclassification of study subjects thereby 
introducing a misclassification bias. 
Internal Validity 
Internal validity refers both to how well a study was run (research design, operational 
definitions used, how variables were measured, what was/wasn't measured), and how 
confidently one can conclude that the observed effect(s) were produced solely by the 
independent variable of interest and not extraneous ones. 
External Validity 
External validity is the ability the apply the results obtained from a study beyond the 
study population. To do so, we must know to what extent the study population is 
representative of all patients with the disease in question (breast cancer in our case). 
For Survival Analysis 
Mortality 
Mortality rate is a measure of the number of deaths (all cause or breast cancer specific) in 
a population, scaled to the size of that population, per unit of time. Mortality rate is 
typically expressed in units of deaths per 1000 individuals per year; thus, a mortality rate 
of 9.5 (out of 1000) in a population of 100,000 would mean 950 deaths per year in that 
entire population. The term "mortality" is also sometimes inappropriately used to refer to 
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the number of deaths among a set of diagnosed hospital cases for a disease or injury, 
rather than for the general population of a country or ethnic group. This disease mortality 
statistic is more precisely referred to as "case fatality". 
Survival 
Survival rate refers to the percentage of people in a study or treatment group who are 
alive for a certain period of time after they were diagnosed with or treated for a disease, 
such as breast cancer. The survival rate is often stated as a five-year survival rate, which 
is the percentage of people in a study or treatment group who are alive five years after 
diagnosis or treatment. Also called overall survival rate. It is important to note that while 
mortality may be high, survival of the patients might be extremely good. 
Prognosis 
Prognosis is a medical term for predicting the likely outcome of an illness, often 
involving a detailed description.A complete prognosis includes the expected duration, the 
function, and a description of the course of the disease. Prognostic indicators are 
situations or conditions, or characteristics of a patient, that can be used to estimate the 
chance of recovery from a disease or the chance of the disease recurring. 
Time to event and censoring 
Time to event data arise when interest is focused on the time elapsing before an event is 
experienced. They are known generically as survival data, since death is often the event 
of interest, particularly in cancer and heart disease. Timetoevent data consist of pairs of 
observations for each individual: (i) a length of time during which no event was 
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observed, and (ii) an indicator of whether the end of that time period corresponds to an 
event or just the end of observation. Participants who contribute some period of time that 
does not end in an event are said to be ‗censored‘. Their event-free time contributes 
information and they are included in the analysis. Time-to-event data may be based on 
events other than death, such as recurrence of a disease event (for example, time to the 
end of a period free of epileptic fits) or discharge from hospital. 
Life tables and Kaplan Meier Method 
A life table is a table which shows the survival probability of a group of patients wherein 
the survival time is divided into a certain number of intervals. For each interval we can 
then compute the number and proportion of cases that entered the respective interval 
"alive," the number and proportion of cases that failed in the respective interval (i.e., 
number of terminal events, or number of cases that "died"), and the number of cases that 
were lost or censored in the respective interval. This statistical method is similar to the 
Kaplan Meier method of estimating survival. 
The Kaplan Meier Product-Limit method has been considered as a gold standard for 
many years when it comes to graphical displays of survival data. A Kaplan-Meier 
analysis allows estimation of survival over time, even when patients drop out or are 
studied for different lengths of time. For each interval of time (say 1 year), survival 
probabilities are calculated as number of patients surviving / number of patients at risk. 
Patients who have died or lost to follow up (censored) are not counted in the 
denominator. Probability of surviving to any point is estimated from the cumulative 
probability of surviving each of the preceding time intervals (calculated as the product of 
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preceding probabilities)[160]. The advantage of the Kaplan Meier Product-Limit method 
over the life table method for analyzing survival and failure time data is that the resulting 
estimates do not depend on the grouping of the data (into a certain number of time 
intervals). 
Comparing the proportion surviving after computing the survival curves for two sets of 
patients would only give us a comparison at some arbitrary time point. In order to 
compare the total survival experience between two sets of patients, the logrank test is 
more useful [161]. The logrank test is used to test the null hypothesis that there is no 
difference between the populations inthe probability of an event (here a death) at any 
time point. The analysis is based on the times of events (here deaths). For each such time 
we calculate the observed number of deaths in each group and the number expected if 
there were in reality no difference between the groups.If a survival time is censored, that 
individual is considered to be at risk of dying in the time interval of the censoring but not 
in subsequent weeks. This way of handling censored observations is the same as for the 
Kaplan-Meier survival curve. The logrank test is based on the same assumptions as the 
Kaplan Meier survival curve namely, that censoring is unrelated to prognosis, the 
survival probabilities are the same for subjects recruited early and late in the study, and 
the events happened at the times specified. Since the logrank test is purely a test of 
significance it cannot provide an estimate of the size of the difference between the groups 
or a confidence interval. 
Relative survival 
Relative survival is defined as the ratio of the proportion of observed survivors in  
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cohort of cancer patients to the proportion of expected survivors in the background 
population with same age and period distribution[156]. The formulation is based on the 
assumption of independent competing causes of death. The relative survival adjusts for 
the general survival of the Singapore population for that race, sex, age and year. Thus the 
relative survival is a net survival measure representing cancer survival in the absence of 
other causes of death. 
 Relative survival provides an estimate of the excess mortality in the patient pool directly 
or indirectly associated with cancer (in our study, breast cancer) [156, 162]. It thus gives 
an estimate of the disease related deaths (excess deaths) in the patient population after 
assuming that the general population is free from that particular disease (breast cancer in 
this case). 
Excess mortality can be represented in the following manner: 
Excess mortality = Observed Mortality – Expected Mortality 
A major advantage of relative survival is that information on cause of death is not 
required. This eliminates problems associated with the inaccuracy or non-availability of 
death certificates. We obtain a measure of excess mortality experienced by patients 
diagnosed with breast cancer irrespective of whether the excess mortality is directly or 
indirectly attributable to the cancer.  
The central issue in estimating relative survival is defining a ―comparable group from the 
general population.‖ If not all the excess mortality is due to breast cancer, it would lead to 





Student‘s t-test, is a method of testing hypotheses about the mean of a small sample 
drawn from a normally distributed population when the population standard deviation is 
unknown. The null hypothesis states that there is no effective difference between the 
observed sample mean and the hypothesized or stated population mean, i.e., any 
measured difference is due only to chance.It is most commonly applied when the test 
statistic follows a normal distribution. 
Mann Whitney U test 
The Mann-Whitney U Test is used to compare differences between two independent 
groups when the dependent variable is either (a) ordinal or (b) interval but not normally 
distributed. The Mann-Whitney U test is often viewed as the nonparametric equivalent of 
Student's t-test. Like the parametric Student's t-test, the non- parametric Mann-Whitney U 
test (1) is used to determine if a difference exists between two "groups," however you 
define "groups‖; (2) is ideally dependent on random selection of subjects into their 
respective group. The major difference between the Mann-Whitney Test and Student's t-
Test involves the concept of  normal distribution: 
 Mann-Whitney is a nonparametric test.  





Chi Square Test 
The chi-square test is used to determine whether there is a significant difference between 
the expected frequencies and the observed frequencies in one or more categories. The chi 
square test tests the null hypothesis that there is no significant difference in the number of 
observed and expected frequencies in each category. 
The Chi square value for a given contingency table can be calculated as follows: 
X
2
 = (O - E)
2
 / E 
Where O is the Observed Frequency in each category 
E is the Expected Frequency in the corresponding category 
df is the "degree of freedom" (n-1) where n is the number of categories 
X
2
 is Chi Square. 
Logistic regression analysis 
Logistic regression is used to predict the probability of occurrence of an event in a group 
of patients by fitting the data to a logistic function curve. Logistic regression is useful in 
describing the relationship between one or more independent variables (ethnicity, tumor 
characteristics, treatment etc in our studies) and a binary response variable (dead or alive, 
young or old and so on). The goal of logistic regression is to correctly predict the 
category of outcome for individual cases using the most parsimonious model. To 
accomplish this goal, a model is created that includes all predictor variables that are 
useful in predicting the response variable. Several different options are available during 
model creation. Variables can be entered into the model in the order specified or logistic 
46 
 
regression can test the fit of the model after each coefficient is added or deleted, called 
stepwise regression. Backward stepwise regression is usually preferred method of 
exploratory analyses, where the analysis begins with a full or saturated model and 
variables are eliminated from the model in an iterative process. The fit of the model is 
tested after the elimination of each variable to ensure that the model still adequately fits 
the data.When no more variables can be eliminated from the model, the analysis has been 
completed. 
The output of a logistic regression analysis is an ―odds ratio‖. An odds ratio is a measure 
of effect size that describes the strength of an association between two binary data values. 
It is the ratio of the odds of an event occurring in one group to the odds of an event 
occurring in another group. 
 
Hosmer Lemeshow test 
The Hosmer–Lemeshow test is a statistical test for goodness of fit (calibration) for 
logistic regression models. It tests the null hypothesis that there is no significant 
difference in the observed mortality risk and model predicted mortality risk [163].If the 
Hosmer and Lemeshow Goodness-of-Fit test statistic is .05 or less, we accept the null 
hypothesis that there is no difference between the observed and model-predicted values 
of the dependent. (This means the model predicted values significantly differ from what 
they ought to be, which is the observed values).  If the H-L goodness-of-fit test statistic is 
greater than .05, as we want for well-fitting models, we fail to reject the null hypothesis 




Concordance (c)  statistic 
 The c statistic is used to determine the descriminative power of a model. Discrimination 
refers to the ability to distinguish high risk subjects from low risk subjects.The 
interpretation of the c statistic is equivalent to the area under the receiver operating 
characeristic curve for a binary outcome variable (dead or alive) [164], that is, a c statistic 
of 0.5 indicates no discrimination above chance, whereas a c statistic of 1.0 indicates 
perfect discrimination. For this thesis, the c statistic was computed to determine whether 
one prognostic model was superior in predicting survival to another. 
Net Reclassification Index (NRI) 
The Net Reclassification Index assesses the ability of a model including a new prognostic 
marker to more accurately reclassify individuals into higher or lower risk strata. The NRI 
is the difference in proportions of patients moving up and down risk strata (high, 
moderate and low risk of mortality) among patients with the event of interest versus those 
without. The NRI is similar to the simple percentage reclassified but distinguishes 
between movements in the correct direction (up for case patients (deaths) and down for 
control patients (survivors) [165]. 
The NRI is calculated as follows: 
Pup,event  = number of events moving up / number of events 
Pdown,event = number of events moving down / number of events 
Pup,nonevent = number of nonevents moving up / number of non events 
 Pdown,nonevent = number of nonevents moving down / number of non events 
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NRI = (Pup,event  - Pdown,event) – (Pup,nonevent - Pdown,nonevent) 
Where ―up‖ refers to the patients moving up in the risk stratas based on the new model 
when being compared to the old model and ―down‖ refers to the patients moving down in 
the risk stratas based on the new model when being compared to the old model. For this 
thesis, ―event‖ refers to ―dead‖ while nonevent refers to ―alive‖. 
Cox proportional hazards regression analysis 
Survival analysis examines and models the time it takes for events to occur. Survival 
analysis focuses on the distribution of survival times. Although there are well known 
methods for estimating unconditional survival distributions, most interesting survival 
modeling examines the relationship between survival and one or more predictors, usually 
termed ―covariates‖. 
Proportional Hazard model is a type of survival analysis model in statistics. Survival 
models can be viewed as consisting of two parts: the underlying hazard function, often 
denoted λ0(t), describing how the hazard (risk) changes over time at baseline levels of 
covariates; and the effect parameters, describing how the hazard varies in response to 
explanatory covariates[166, 167].The effect of covariates estimated by any proportional 
hazards model is called the ―Hazard Ratio‖. 
Throughout this thesis, for all survival analysis, the outcome of interest was overall 
survival. All multivariate Cox proportional hazard analysis was applied (a) to calculate 
adjusted mortality risks for the patient groups of interest and (b) to identify which 
combination of factors best predicted overall survival. For this we entered all variables 
univariately associated with overall survival with a p-value <0.2 into the model and used 




A hazard is the rate at which an event happens, so that the probability of an event 
happening in a short time interval is the length of the time multiplied by the hazard. 
Although the hazard may vary with time, the assumption in proportional hazard models 
for survival analysis, is that the hazard in one group is a constant proportion of the hazard 
in the other group which means that in a regression type of setting, the survival curves for 
the groups must have a hazard function that is proportional over time (i.e., constant 
relative hazard). This proportion is the hazard ratio. Thus the hazard ratio is an expression 
of the hazard or chance of an event occurring in one arm as a ratio of the hazard of the 










Chapter 4 Comparison of presentation and outcome of 
Singaporean breast cancer patients with Malaysian and SEER 
breast cancer patients 
Comparison of presentation and outcome of breast cancer patients between a middle 
income country (Malaysia) and a high income country (Singapore) 
(Accepted for publication as ―Breast cancer in South East Asia: Comparison of 
presentation and outcome between a middle income and a high income country.‖ in the 
World Journal of Surgery 2012) 
Introduction: 
Asia is the world‘s largest and most populous continent comprising over 60% of the 
world‘s population. Except for a few countries (Singapore, Taiwan, Hong Kong, Japan, 
South Korea, Israel, Saudi Arabia, and Macau) that are classified as high-income 
countries, the rest of Asia includes low- and middle-income countries [7, 29]. Over the 
past decades, South East Asia has seen large differences in socio-economic growth, 
leading to sharp contrasts in health-systems developments between countries [29]. 
Compared to Western countries where breast cancer incidence rates have stabilized or 
even decreased over the last two decades [168-170], most Asian countries have seen a 
rapid rise in breast cancer incidence [4-6, 40, 171]. With the Westernization of Asian 
countries, changes in dietary pattern and increased exposure to environmental and 
reproductive risk factors among Asian women, it is quite likely that in the near future, the 
majority of the breast cancer patients will be of Asian descent. 
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Singapore is a newly industrialized Asian country where approximately 75% of the 
population is Chinese, 14% is Malay and 9% is Indian [172]. Classified as a high income 
Asian country, Singapore sees a 95% literacy rate and a life expectancy at birth of 81 
years [173]. Rapid economic growth and low unemployment rates[173] have converted 
Singapore from a developing to a developed country within three decades [174]  with 
rising standards of living and advanced healthcare facilities. Healthcare systems in 
Singapore have undergone major reforms from the early 1960s (when decentralization 
took place) to the early 1980s where the National Health Plan outlined a 20 year plan to 
modernize healthcare facilities and raise medical standards[175]. Current healthcare 
provision in Singapore is considered at par with that from other developed 
countries[175]. 
Like Singapore, Malaysia also comprises of three major ethnic groups i.e., Malay 
(~54%), Chinese (~26%) and Indians (~8%) [176] with a life expectancy at birth of 74 
years [177]. An upper middle income country [177], Malaysia has seen sustained 
economic growth over the past few years with an increasing proportion of people falling 
in the middle class category [178]. Although healthcare systems in Malaysia have 
undergone significant improvements over the last three decades, there are still gaps in 
terms of resource allocation, funding and infrastructure that need to be filled before 
Malaysian healthcare can be considered at par with that from other developed countries 
[179]. 
Several studies in the West have shown that breast cancer occurs more frequently in 
developed countries and among women with a high socioeconomic status (SES) [3, 75-
78]. Incidence rates of breast cancer in Singapore (developed country) and Malaysia (less 
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developed country) are 60.0  and 46.2  per 100,000 respectively[35, 180]. Survival after 
breast cancer, on the other hand, is generally lower in low income countries and in 
women with a low SES or educational level [76, 181]. 
This study compares breast cancer presentation, treatment and outcome of patients from 
two neighboring countries in South East Asia with different levels of development.  
Methods: 
Data for this study was obtained from the Singapore Malaysia Breast Cancer Hospital 
Based Registry [1]. This registry combines data from two hospital based registries, i.e., 
the National University Hospital (NUH) breast cancer registry, (Singapore, high income 
country) and the University of Malaya Medical Center (UMMC) hospital based registry, 
(Kuala Lumpur, Malaysia, middle income country). 
The NUH breast cancer registry started in 1995 and contains information on 2,449 
consecutive breast cancer patients diagnosed between 1990 and 2007 (data for patients 
diagnosed from 1990-1995 was collected retrospectively).From the NUH registry we 
selected2,141 patients diagnosed between 1993 and 2007. The UMMC breast cancer 
registry started in 1993 contains information on 3,320 patients diagnosed between 1993 
and 2007. Details on both these registries are described elsewhere [1, 38]. In both centers, 
patients were monitored through follow-up in the specialist outpatient clinics. Data on 
mortality were obtained from the hospitals‘ medical records, as well as active follow-up 
through the patients‘ next-of-kin. Follow up for each patient was calculated from the date 
of diagnosis to the date of death or end of follow up (July 2010 for NUH patients and 
November 2010 for UMMC patients). 
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For individual patients, the registry provides information on age at diagnosis,  ethnicity 
(Chinese, Malay, Indian and other), Estrogen Receptor (ER) and Progesterone Receptor 
(PR) status (if ≥10% of epithelial tumor cells expressing receptors, negative and 
unknown), stage (in situ, I, II, III, IV and unknown), differentiation (good, moderate, 
poor, unknown), tumor size (continuous), nodal status (pN0, pN1, pN2, pN3 and 
unknown), regional nodes (0, 1-3, 4-9 and 10 or more). Treatment variables included type 
of surgery (mastectomy, breast conserving surgery [BCS] and no surgery), radiotherapy 
(yes/no), chemotherapy (yes/no), hormone therapy (yes/no) and noeadjuvant 
chemotherapy (yes, no and unknown). 
Statistical analysis: 
Demographics, tumor characteristics and treatment received by patients at the National 
University Hospital (Singapore) (n=2,141) or the University of Malaya Medical Center 
(Kuala Lumpur, Malaysia) (n=3,320) were compared using logistic regression analysis. 
Age at diagnosis and tumor size (as continuous variables) were presented as a median and 
compared with Mann Whitney U test. 
Proportion of patients receiving adequate (standard) treatment (defined as surgery for 
patients with stage in situ, I, II or III,  chemotherapy for patients with ER negative lymph 
node positive invasive tumors, hormone therapy for patients with ER positive tumors and 
radiotherapy for patients treated with breast conserving surgery) were compared between 
the two institutions using the Chi Square Test. 
Kaplan Meier analysis and logrank test were used to compare overall survival between 
countries and Cox regression analysis was used to estimate the adjusted relative risk of all 
cause mortality for patients treated in Singapore as compared to those treated in 
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Malaysia. In order to get insight into the factors contributing to survival disparities, we 
entered all variables, univariately associated with survival, into a multivariate Cox model 
in a stepwise manner. The first model consisted of crude Hazard Ratios (HRs) 
representing the relative risk of death of patients from Malaysia as compared to those 
from Singapore. The second model presented hazard ratios adjusted for age at diagnosis, 
year of diagnosis and ethnicity. The next model was additionally adjusted for tumor 
characteristics (i.e. tumor size, grade, nodal status and ER status) and the final model was 
additionally adjusted for type of surgery, radiotherapy, chemotherapy and hormone 
therapy. 
All analysis were performed using SPSS Version 16 and any p value <0.05 was 
considered significant. 
Results: 
The median follow up for the Malaysian and Singaporean patients was 5.1 years and 6.1 
years respectively. Malaysian and Singaporean patients presented at similar ages (median 
age 50 years for both countries). Malaysian patients were less likely to be diagnosed with 
in situ breast cancer than patients from Singapore (Adjusted Odds Ratio (ORadj) 0.2; 
95% CI 0.1 to 0..3) and more likely to be diagnosed with advanced disease [(22.3% vs 
14.4% respectively for stage III; ORadj 1.6; 95% CI 1.3 to 2.0); 10.8% vs 7.9% 
respectively for stage IV; ORadj 1.2; 95% CI 1.1 to 1.4)] as compared to Singaporean 
patients (Table 4.1a). The tumor size at presentation for the Malaysian patients was larger 
than that of Singaporean patients (median tumor size 30mm compared to 22mm, p 
<0.001). Malaysian patients were more likely not to undergo surgery for stage I-III 
disease (9.0% vs 0.6% respectively; p value <0.001) (Table4.1b).Malaysian patients with 
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invasive, non-metastatic disease were less likely to receive radiotherapy (RT) following 
BCS as compared to the Singaporean patients (78.0% vs 89.8% respectively, p value 
<0.001) (Figure 4.1). Malaysian women were just as likely to receive chemotherapy for 
estrogen receptor (ER) negative lymph node (LN) positive disease (87.6% compared 
to90.1%, p value >0.05) and hormone therapy for ER positive disease (91.2% compared 
to 89.1%, p value >0.05) as the Singaporean patients. 
 
 
Table 4.1a Patient and tumor characteristics by place of diagnosis and the likelihood of 
these characteristics being associated with being diagnosed in Malaysia as determined by 
logistic regression. 
Variable Country Unadjusted OR 
(95% CI) 
Adjusted OR 
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1 
1.1 (0.9 to 1.3) 
1.7 (1.4 to 2.0) 
1.5 (1.2 to 1.8) 
0.1 (0.1 to 0.2) 
 
0.2 (0.1 to 0.3) 
1 
0.8 (0.6 to 1.0) 
1.6 (1.3 to 2.0) 
1.2 (1.1 to 1.4) 















0.6 (0.5 to 0.8) 
1 
0.8 (0.7 to1.0) 
 
0.4 (0.3 to 0.9) 
1 
0.5 (0.4 to 0.8) 
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Unknown 961 207 3.1 (2.6 to 3.7) 2.9 (2.2 to 3.8) 
Tumor Size*
^a 
Median (Range) in mm 
0.1 to 2 cm 

















0.6 (0.5 to 0.7) 
1 
1.8 (1.5 to 2.2)) 
0.1 (0.1 to 0.2) 
 
 
0.9 (0.7 to 1.1) 
1 
1.5 (1.1 to 1.9) 





















0.1 (0.1 to 0.2) 
0.3 (0.2 to 0.4) 
1.4 (1.2 to 1.7) 
1 
1.7 (1.4 to 2.0) 
 
0.1 (0.1 to 0.2) 
0.3 (0.2 to 0.4) 
1.5 (1.2 to 1.8) 
1 


























1.0 (0.9 to 1.2) 
1.0 (0.8 to 1.2) 
1.4 (1.1 to 1.8) 




0.8 (0.6 to 0.9) 
0.7 (0.5 to 0.9) 
1.1 (0.8 to 1.5) 
0.1 (0.1 to 0.3) 
* Valid proportions have been calculated 
^ Excluding In situ  patients 
a
 Logistic regression model adjusted for age, ethnicity, ER status and PR status. All other ORs are adjusted for age, 
ethnicity, ER status, PR status and stage. 
#
 Mann Whitney U test p value <0.001 
b
 Mann Whitney U test p value  >0.05 
 
Table 4.1bTreatment administered to stage I, II and III patients from Malaysia and 
Singapore and the likelihood of treatment being associated with being diagnosed in 
Malaysia as determined by logistic regression. 
Variable Country Unadjusted OR 
(95% CI) 
Adjusted OR 

















19.9 (10.9 to 37.9) 
1 
1.0 (0.9 to 1.5) 
 
20.6 (11.4 to 50.2) 
1 












0.9 (0.8 to 1.0) 
 
1 












1.0 (0.9 to 1.1) 
 
1 












0.6 (0.5 to 0.7) 
 
1 


















0.7 (0.5 to 1.0) 




0.3 (0.2 to 0.4) 
0.1 (0.1 to 0.2) 
* Valid proportions have been calculated 




Two hundred and nine (10.8%) Singaporean patients and 610 (18.9%) Malaysian patients 
with invasive breast cancer received incomplete locoregional treatment defined as no 
surgery or BCS without RT or ER negative LN positive without chemotherapy or ER 
positive without hormone therapy. 
The 5 year overall survival for Malaysian patients was substantially lower than that of 
Singaporean patients (69.0% compared to80.0%, logrank test p <0.001) (Figure 4.2). 
Overall survival estimates for both countries improved with calendar time with the 
improvement in survival being stronger for Malaysia (5 year survival estimates for 
Malaysians diagnosed between 1993-2000 and 2001-2007 were 62.0% and 73.0% 
respectively while for the Singaporeans, estimates were 79.0% and 81.0% respectively) 
(Table 4.2). 
Univariate Cox regression analysis showed that besides country of diagnosis (i.e. 
Singapore or Malaysia),  age at diagnosis, period of diagnosis, ethnicity, ER status, PR 
status, type of surgery, radiotherapy, chemotherapy, hormone therapy, regional nodes 
examined, nodal status,  cell differentiation (grade), tumor size and receipt of 
neoadjuvant chemotherapy were significantly associated with risk of all cause mortality. 
Table 4.2 Five year overall survival estimates for Malaysia and Singapore patients 




Malaysia (N= 3,225) Singapore (N=1,939) 





62.0% (59.4% to 64.5%) 
73.0% (71.8% to 74.6%) 
 
79.0% (77.5% to 80.5%) 







93.0% (91.9% to 94.1%) 
79.0% (77.8% to 80.3%) 
52.0% (49.4% to 54.6%) 
12.0% (6.8% to 17.1%) 
 
98.0% (97.0% to 99.0%) 
85.0% (83.7% to 86.3%) 
66.0% (62.5% to 69.6%) 
23.0% (16.6% to 29.5%) 
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Figure 4.1 Country stratified differences in proportion of: Stage in situ, I, II and III 
patients receiving surgery, ER negative LN positive patients receiving chemotherapy, ER 
positive patients receiving hormone therapy, patients receiving BCS followed by 
radiotherapy and ER positive LN positive patients receiving chemotherapy. (Excluding 

















































p value <0.001 

















































3,225 2,965 2,710 2,466 2,020 1,641 1,313 1,076 826 624 
Number 
of deaths 





1,939 1,788 1,578 1,465 1,359 1,171 996 791 593 417 
Number 
of deaths 
52 97 74 51 62 28 17 19 10 1 
 
Multivariate Cox regression analysis showed that country of diagnosis remained 
independently and significantly associated with survival, even after adjusting for tumor 
characteristics and treatment in a stepwise manner (Table 4.3a), with patients diagnosed 
and treated in Malaysia having a 67% higher mortality risk than patients diagnosed in  
Singapore (Adjusted Hazard Ratio [HRadj]1.67, 95% CI 1.44 to 1.92) (Table 4.3b). 
Patients diagnosed in both countries receiving incomplete locoregional treatment or no 
Logrank test p value <0.001  
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surgery for invasive disease had similar risk of death while Malaysian patients receiving 
chemotherapy or presenting with node negative disease had a significantly higher risk of 
death as compared to their Singaporean counterparts (Table 4.3c). 
Table 4.3a Stepwise modeling for Cox Regression analysis for all cause mortality of 
Malaysian patients compared to Singaporean patients 
Model Hazard Ratios adjusted for stated variables 
a Unadjusted Hazard Ratio representing relative risk of death of Malaysian patients as compared 
to Singaporean patients 
b Hazard Ratio adjusted for, year of diagnosis, age and ethnicity 
c Hazard Ratio adjusted for variables in ‗b‘ plus tumor size, grade, nodal status and ER status 
d Hazard Ratio adjusted for variables in ‗c‘ plus surgery type, radiotherapy, chemotherapy and  
hormone therapy 
 
Table 4.3b Cox regression models for all cause mortality of Malaysian patients 
compared to Singaporean patients (excluding in situ patients) 
 Total Singapore Malaysia 
Number of patients 


























 1 (ref) 1.67 (1.44 to 1.92) 
 
Discussion: 
This study highlights important differences in survival between breast cancer patients 
from tertiary hospitals in Singapore (high income country)and Malaysia (middle income 
country), Despite only small differences in way of presentation and access to treatment, 
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Malaysian patients more than 70% likely to die within the first five years after diagnosis. 
This increased risk was not explained by more advanced staging and less optimal 
treatment. 
Breast cancer survival disparities between countries have been well documented and 
studies have shown that patients from countries with enhanced diagnostic facilities and 
up to date treatment options have better survival rates [182-187].  Although incidence 
rates of breast cancer are lower in middle income countries as compared to high income 
countries, 55% of breast cancer deaths occur in low income countries and this can be 
attributed to two major determinants namely, late stage at presentation and inadequate 
treatment [188, 189]. In a comparative study of 12 countries in Africa, Asia and Central 
America, differences in cancer outcome correlated with level of development of health 
services [190]. 
Differences in presentation between Singaporean and Malaysian patients could be a result 
of a higher level of health systems development in Singapore, where screening is more 
commonplace and diagnostic and healthcare facilities are advanced as compared to 
Malaysia. However, social and cultural factors are likely to play a role as well. In 
Malaysia, factors like lower awareness about the disease and or inhibition to approach 
physicians due to cultural taboos are more prevalent [35].  
Like for presentation, we only found small differences in treatment patterns between 
patients from the two countries. Singaporean patients were more likely to receive 
standard treatment (radiotherapy in case of treatment with BCS, and surgery for non 
metastatic disease) as compared to the Malaysians. However, the differences were small. 
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Table 4.3c Subgroup analysis - Multivariate Cox regression models for all cause 















































































































































































































































a Cox model adjusted for age, ethnicity, year of diagnosis, tumor size, grade, nodal status, surgery type, radiotherapy,  
  chemotherapy, hormone therapy, distant metastasis 
b Cox model adjusted for age, ethnicity, year of diagnosis, tumor size, grade, nodal status, ER status, radiotherapy, 
chemotherapy, hormone therapy, distant metastasis 
c Cox model adjusted for age, ethnicity, year of diagnosis, grade,  ER status, radiotherapy, chemotherapy, Surgery type, 
   hormone therapy 
d Cox model adjusted for age, ethnicity, year of diagnosis, tumor size, grade, nodal status, ER status 
e Cox model adjusted for age, ethnicity, year of diagnosis, tumor size, grade,  ER status, radiotherapy, chemotherapy, 
Surgery type, hormone therapy, 
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f Cox model adjusted for age, ethnicity, year of diagnosis, tumor size, grade, nodal status, ER status, radiotherapy, 
Surgery type hormone therapy,  
* Incomplete locoregional treatment defined as no surgery or breast conserving surgery without radiotherapy or ER 
negative lymph node positive without chemotherapy or ER positive without hormone therapy 
# Complete locoregional treatment defined as mastectomy or breast conserving surgery followed by radiotherapy or ER 
negative lymph node positive with chemotherapy or ER positive with hormone therapy. 
^ Only stage I, II and III patients included 
 
Large differences in breast cancer survival rates between Singaporean and Malaysian 
patients highlight a scope for improvement in the management of breast cancer in 
Malaysia. Several factors such as differences in population structure (life expectancy) 
[191, 192], low access to  screening [57, 67], lower socioeconomic status [181, 193], low 
access to high quality healthcare[35], poor treatment compliance[120, 194], poor lifestyle 
after diagnosis [195]among Malaysians could explain the disparities in survival compared 
to Singaporean patients. While mortality risks of patients who did not receive standard 
treatment (incomplete locoregional treatment or no surgery) were similar in both groups, 
Malaysian patients receiving complete locoregional treatment had 84% increased risk of 
mortality compared to Singapore patients. This could be due to differences in treatment 
regime administered to patients from the two countries, especially the choice of 
chemotherapeutic agents, or perhaps even the extent of surgery. Also differences in 
compliance with treatment may explain part of the difference. However, details of 
chemotherapeutic agents or duration of therapy were not available and hence gauging the 
impact of differences in chemotherapy regimen on survival could not be made. Several 
studies have shown that type of treatment received is associated with breast cancer 
survival [32, 107, 196, 197] but from our study, it is unlikely that differences in receipt of 
treatment between patients from the two countries would explain the survival differences 
as the stepwise adjusted Hazard Ratios (adjusting for demographic characteristics 
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followed by adding tumor characteristics and finally treatment to the Cox model)  did not 
differ significantly from the unadjusted HR. 
Another possible explanation for the survival differences could be due to differences in 
screening practices between the two countries. Singapore has implemented a structured 
screening program for all women aged 50 years to 69 years from 2002 [55], although the 
response rate for the same is not too high. In contrast, Malaysia practices only 
opportunistic screening[198]. Thus large number of in situ patients from Singapore as 
compared to Malaysia, suggests that lead time bias (artificial prolonging of survival time 
due to early detection) could also account for longer survival for Singaporean patients 
when compared to Malaysian patients. 
We acknowledge that our study suffers from several shortcomings, including a relatively 
short follow up time for patients from both countries.In addition, we assessed all cause 
mortality as our end point as no data on cause of death was available. Thirdly, being a 
hospital based study rather than a population based study, extrapolate these findings to 
the general population of the respective countries might not be feasible. However, the 
catchment area of NUH, Singapore, which treats an estimated 10% of breast cancer cases 
in Singapore, sees patients with demographics that are not different from other areas of 
the country [38]. UMMC in Kuala Lumpur, Malaysia, serves a predominantly middle 
income urban population and hence our findings may not necessarily reflect the overall 
situation of breast cancer in Malaysia [1], for example, the presentation of breast cancer 
in the rural Malaysian settings for instance, may be more advanced than in our study [1]. 
Another limitation of our study is that some prognostic factors, such as co-morbidity, 
body mass index (BMI), HER2/neu status, and local/systemic recurrence were largely 
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missing and hence their impact on our results will be difficult to gauge. Also, the impact 
of certain factors such as SES, treatment compliance and education level on the 
differences in survival between Singaporean and Malaysian patients was not assessed. 
Conclusion: 
Differences in way of presentation and treatment of patients with breast cancer were 
small except for certain tumor characteristics like tumor size and stage at presentation 
between Singaporean and Malaysian patients. Patients from Malaysia present slightly 
more often with advanced stage and unfavorable characteristics. The overall survival of 
breast cancer patients from Malaysia is much lower than that of Singaporean patients. 
Poorer compliance with treatment, unfavorable life style factors and competing risks can 
potentially explain the higher mortality risk of Malaysian breast cancer patients and these 











Differences in outcome between Singaporean and Surveillance Epidemiology and End 
Results (SEER;USA) breast cancer patients 
Introduction: 
Breast cancer incidence rates are on the rise in South East Asia, where in some countries 
rates have tripled over the last three decades [5, 16, 40]. Although incidence rates of 
breast cancer are still higher in Western countries than Asian countries, rates in Asia are 
increasing more sharply. Hence it is quite likely that in the near future, a majority of 
breast cancer patients will be of Asian origin. 
Differences in breast cancer survival rates between countries have been studied 
extensively [39, 182, 183, 199, 200] and several studies have compared the breast cancer 
survival rates of Asian and Western countries [39, 186, 201-203]. Some of these studies 
showed poorer survival rates for Asian women when compared to their Western 
counterparts [186, 204, 205] while other studies concluded otherwise [201, 206, 207]. 
Patterns in breast cancer survival are a composite effects of a multitude of factors 
including predominantly the severity of disease and administration of adequate treatment 
[208]. Differences in breast cancer survival rates between countries can be attributed to 
differences in socioeconomic background, health insurance systems, access to early 
detection, access to and compliance with standard treatment [209-211], variation in tumor 
biology and lifestyle after treatment [186, 212, 213].  
This study aims to highlight differences in presentation and survival of breast cancer 
patients diagnosed in a tertiary teaching hospital in Singapore compared to those in the 




For this study we used data from the Breast Cancer Registry of a tertiary teaching 
hospital in Singapore and the SEER registry [214]. 
The Breast Cancer Registry of the tertiary teaching hospital in Singapore was established 
in 1995, through prospective data collection on demographics, tumor characteristics, 
treatment and follow up of all patients presenting with invasive or in situ breast cancer. 
Data from 1990 to 1995 was collected retrospectively from medical records. Vital status 
information for a majority of the patients was determined through long term follow up 
clinics. For those patients that did not undergo regular follow up at the hospital, contact 
was made via telephone or letter annually. Women were followed until death or end of 
follow up (31
st
 December 2007), whichever came first. The hospital Breast Cancer 
Registry has been approved by the respective Institutional Ethics Review Board. 
We included all 2,302 patients diagnosed with invasive breast cancer between 1990 and 
2007 at the tertiary teaching hospital in Singapore. From the SEER registry, we selected 
female patients diagnosed with invasive breast cancer during the same period (1990-
2007) [214]. The SEER database is a compilation of data on cancer patients (incidence, 
survival, demographics, cancer site, morphology, stage and follow up) from eighteen 
geographic areas of the United States, which together represent approximately 26 percent 
of the US population [215]. 
Variables of interest included: Age at diagnosis (categorized into <40 years, 40 to 59 
years and ≥ 60 years), stage at presentation (I, II, III and IV) and ethnicity [Chinese and 
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non Chinese (i.e., Malays, Indians and others) for Singapore and non Hispanic Whites 
and Blacks for US]. 
Statistical Analysis: 
Age and stage at presentation were compared between the Singaporean and SEER 
patients  using the Chi Square test. Five year relative survival estimates were computed 
according to country, stage, age and ethnicity, using the Singapore population mortality 
data and the US background population mortality data respectively. For details on 
relative survival, refer to chapter 3. 
 In addition, relative survival estimates were computed for Singaporean patients by stage 
and receipt of treatment (Standard treatment: Breast Conserving Surgery (BCS) + 
Radiotherapy (RT) or Mastectomy +/- RT or Estrogen Receptor (ER) positive + 
Hormone therapy or ER negative Lymph Node (LN) positive + Chemotherapy. Non 
Standard treatment: BCS alone or no surgery or ER positive without Hormone therapy or 
ER negative LN positive without Chemotherapy). Relative survival is defined as the ratio 
of the proportion of observed survivors in cohort of cancer patients to the proportion of 
expected survivors in the background population with same sex, age and period 
distribution [156].  
In order to estimate the excess mortality among Singaporean patients within 5 years of 
diagnosis, we applied the 5 year relative survival rates of the  SEER patients to the 
Singaporean patients.We adopted an approach used by Abdel-Rehman et al and Richards 
et al [216, 217] and applied the following formulae to calculate the excess mortality in 
Singapore [216, 217] : 
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Excess mortality = Observed mortality – Expected mortality 
Observed mortality = (complement of 5 year Relative Survival Rate for  
Singapore) X number of patients 
Expected mortality = (complement of 5 year Relative Survival Rate for SEER) 
 X number of patients 
 
Results: 
The median age of the 2,302 Singaporean breast cancer patients was 50 years (range 22 
years to 93 years) and for the 624,942 SEER patients was 61 years. Patients and tumor 
characteristics and treatment received by Singaporean patients are listed in table 4.4.   A 
higher proportion of Singaporean patients presented with late stage disease as compared 
to SEER  patients (9.1% compared to 4.9% for stage IV disease respectively, p <0.001) 
(Table 4.5).  
Ethnic distribution of the two countries followed a similar pattern with each country 
having an ethnic majority (Non-Hispanic Whites (83.7%) for the USA and Chinese 
(77.7%) for Singapore) and other ethnic minorities (Blacks, Hispanic Whites, Asia 









Table 4.4 Patient and tumor characteristics and treatment received by patients at a 
tertiary teaching hospital in Singapore 






































Median (Range) in mm 
0.1 to 2 cm 







































































Table 4.5 Distribution of age and stage at diagnosis for Surveillance Epidemiology and 
End Results (SEER) and Singaporean patients 



















26,868    (7.1%) 
18,495    (4.9%) 
250,039  
 
570   (26.7%) 
1039 (48.7%) 
331   (15.5%) 





0 to 39 years 














* indicates valid proportions have been calculated (i.e., not considering unknowns) 
 
After a median follow up of 2.4 years, five year relative survival estimates for stage I 
diseasewere comparable for the two populations (99.6% for Singapore and 100% for 
SEER) (Table 4.6) . However, for more advanced stages, five year relative survival 
probabilities were lower  for Singapore patients than for SEER patients (81.3% compared 
to 87.8% for stage II, 50.2% compared to 60.0% for stage III and 13.6% compared to 
21.7% for stage IV respectively). Age stratified five year relative survival esimates were 
also poorer for Singaporean patients as compared to SEER patients for each age stratum 
(73.9% compared to 81.6% for patients <40 years at diagnosis, 77.2% compared to 
88.5% for patients aged 40 to 59 years and 68.2% compared to 89.4% for patients aged 
≥60 years respectively) (Table 4.6). For Singaporean patients receiving standard 
treatment, the 5 year overall relative survival estimate was 78.4% compared to 26.6% for 
the patients not receiving non standard treatment (Table 4.6). Analysis based on stage 
stratification and receipt of treatment showed large differences in relative survival 
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estimates with patients within each stage strata having substantially higher survival rates 
when treated with standard treatment as compared to those treated withnon standard 
treatment. Also, patients receiving standard treatment have survival rates similar to SEER 
patients especially for late stage (stage III and IV) disease (Table 4.6). 
Table 4.6 Five year relative survival estimates by stage and age for SEER, USA and a 
tertiary teaching hospital in Singapore. 
   (5 year relative survival estimates) 
SEER, United States Tertiary teaching hospital, Singapore 
Overall Overall Standard treatment N Non standard treatment N 
 
Stage 







88.8% (88.6% to 88.9%) 
100% 
87.8% (87.5% to 88.0%) 
60.0% (50.3% to 60.7%) 
21.7% (21.0% to 22.4%) 
 
 
73.8% (70.5% to 77.1%) 
99.6% (96.1% to 101.6%) 
81.3% (77.5% to 84.6%) 
50.2% (41.9% to 58.1%) 
13.6% (7.7% to 21.4%) 
 
 
78.4% (75.5% to 81.0%) 
100% (96.6% to 101.8%) 
82.8% (79.0% to 86.0%) 
52.8% (44.1% to 60.9%) 










26.6% (18.5% to 35.5%) 
84.7% (27.7% to 99.0%) 
39.5% (16.0% to 63.0%) 
7.6% (1.0% to 38.2%) 









0 to 39  
40 to 59  
≥60  
 
81.6% (81.4% to 81.8%) 
88.5%(88.4 % to 88.6%) 
89.4% (89.3% to 89.5%) 
 
73.9% (66.9% to 79.6%) 
77.2% (74.0% to 80.1%) 
68.2% (61.1% to 74.6%) 
 
76.4% (68.7% to 82.4%) 
80.8% (77.4% to 83.8%) 






33.4% (12.5% to 56.1%) 
21.4% (11.9% to 32.8%) 





*Excluding stage unknown 
Standard treatment: BCS +RT or Mastectomy +/- RT or ER positive + Hormone therapy or ER negative LN positive + Chemotherapy 
Non Standard treatment: BCS alone or no surgery or ER positive w/o Hormone therapy or ER negative LN positive w/o Chemotherapy 
 
Non-Hispanic White SEER patients had the highest five year relative survival 
probabilities while the  Non Chinese (Singaporean) had the worst survival estimates 
(Figure 4.3). These differences persisted after stage stratification (Table 4.7). 
Table 4.7 Five year relative survival estimates by ethnicity for SEER, USA and a tertiary 


















89.7% (89.5% to 89.8%) 
100% 
88.6% (88.4% to 88.9%) 
62.6% (61.8% to 63.4%) 
23.1% (22.3% to 23.9%) 
76.5% (75.9% to 77.0%) 
96.8% (96.0% to 97.5%) 
80% (79.1% to 80.8%) 
44.5% (42.6% to 46.4%) 
14.0% (12.5% to 15.6%) 
77.8% (74.8% to 80.5%) 
99.8% (95.8% to 101.7%) 
83.3% (79.1% to 86.9%) 
53.1% (43.3% to 62.1%) 
14.2% (7.0% to 24.1%) 
62.2% (55.6% to 68.2%) 
98.8% (81.9% to 101.4%) 
72.9% (62.8% to 80.9%) 
41.9% (25.9% to 57.2%) 




Figure 4.3 Relative survival curves for women diagnosed with breast cancer in 




Figure 4.4 shows the Kaplan Meier survival plots for the patients diagnosed at in 
Singapore stratified by stage. Increasing stage decreases overall survival probability. 
Additionally, by plotting the conditional (interval specific) relative survival against the 
time since diagnosis, one can estimate the instantaneous relative survival rate after having 
survived for a certain number of years. The curve for stage IV patients, for example, 
reaches an interval specific relative survival rate of 1 following eight years from the date 
of diagnosis suggesting that if a woman with stage IV disease survives for eight years, 
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Table 4.8 Excess mortality at five years among Singaporean patients. 
Variable Number of cases 
diagnosed with breast 
cancer in Singapore 
Observed  
mortality 5 years 
from diagnosis 
(Using the Singapore 
5 year RSR) 
Expected 
mortality 5 years 
from diagnosis 
(Using the SEER 
5 year RSR) 
Excess mortality 








543    
1015  
324    

















Figure 4.4 Kaplan Meier plots and interval specific relative survival plots for stage I-IV 
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For women with stage II, III and IV disease in Singapore, we observed differences in 
estimated excess mortality (computed using Singaporean patients‘ 5 year RSRs) and 
expected excess mortality (computed using the SEER patients‘ 5 year RSRs) (Table 4.8) 
indicating that some deaths within each stage strata could be reduced if Singapore 
achieved similar stage-specific relative survival  as the USA. Had the SEER stage-
specific survival rates been reached in Singapore, 410 instead of an estimated 529 breast 
cancer deaths would have been observed (reduction of 22.4%). 
Discussion: 
This study shows marked differences in breast cancer presentation and survival between 
Singaporean and SEER patients with Singaporean patients being more likely to be 
diagnosed at a younger age and at a later stage compared to the US patients. Singaporean 
patients had poorer overall 5-year RSRs as well as poorer outcome for late stage disease 
and for all age groups. Ethnic differences in survival were similar between the two 
countries with the ethnic minorities having poorer outcome as compared to the ethnic 
majority in their respective country. The excess mortality among Singaporean breast 
cancer patients when compared to the SEER patients was more than 20%. 
Differences in age at presentation can be explained by the fact that the Singaporean 
population is predominantly young with only 18% of the breast cancer cases being 
diagnosed above the age of 65 years in the last two decades [32, 40]. In contrast, nearly 
50% of all breast cancer cases in USA occur in women aged 65 years or more [218, 219]. 
In addition, postmenopausal breast cancer risk is relatively low among Singaporean 
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patients as compared to their Western counterparts likely due to differences in 
reproductive patterns, hormone replacement therapy use, screening and lifestyle [220]. 
Later stage at presentation for the Singaporean patients could reflect the decreased 
awareness of the Singaporeans regarding breast cancer and its treatment as well as 
limited knowledge about the benefits of early detection. Cultural issues among South 
East Asian women such as fatalism and cultural taboos preventing women from being 
screened may also explain the difference in stage at presentation [30]. In Singapore, the 
prevalence of cancer misconceptions and limited knowledge about cancer warning signs 
and screening are widespread [221] and uptake of mammography screening is low as 
compared to the US [55] .  
Crude overall differences in outcome between American and Singaporean patients were 
large with the Singaporean patients having poorer five year relative survival estimates for 
each stage (except stage I) and all age groups. Very young age at breast cancer diagnosis 
carries a poor prognosis. Since almost 14% of the patients diagnosed at the tertiary 
teaching hospital in Singapore were below the age of 40 years as compared to 5.5% from 
the SEER database, some of the observed survival difference may be explained by 
differences in age distribution [222, 223]. Differences in survival between older patients 
from the two countries can in part be explained by the fact that older Asian patients may 
be more likely to decline treatment due to cultural and financial reasons [32]. 
Additionally, 34.7% of the Singaporean patients presented with estrogen receptor (ER) 
negative tumors whose survival is known to be poor when compared to ER positive 
patients [224]. In comparison 18.6% of the SEER breast cancer patients (diagnosed 
between 1990 and 2001) presented with ER negative tumors [225]. This difference in ER 
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status at presentation could also explain the difference in survival between patients from 
the two countries.  Several other possible explanations for the survival disparities 
between patients from the two regions could be the variations in disease aggressiveness 
[226], suboptimal and lower compliance with treatment for Singaporean patients, 
differences in health seeking behavior, differences in life style factors after cancer, and 
financial and cultural reasons inhibiting Singaporean patients to opt for optimal 
treatment. South East Asian patients are known to have a strong belief in traditional 
medicine [30, 227] and when it comes to treatment, the patient usually involves her 
family members. This in turn could lead to a delay in appropriate therapeutic 
intervention, increasing disease severity and thus affecting the survival probabilities for 
patients from this region. Lead time bias due to more prevalent screening in the West 
compared to Singapore could also account for the better survival rates among SEER 
patients compared to Singaporean patients[57].  These differences in survival highlight a 
scope for improvement in the management and healthcare of breast cancer in South East 
Asia.   
Differences in survival between ethnic groups of the two countries were similar and these 
differences showed that the ethnic minorities (Blacks for USA and Non Chinese for 
Singapore) had poorer survival probabilities than the ethnic majorities. Studies in the 
West have shown that ethnic minorities have worse outcome after breast cancer diagnosis 
[228, 229]. The ethnic distribution of Singapore is such that almost 30% of the population 
is constituted of ethnic minorities, namely Malays and Indians. Ethnic minorities are 
often of a lower socioeconomic status (SES) and low SES is associated with poor 
outcome for breast cancer patients[181].  As our study seems to suggest that the ethnic 
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minorities do perform poorly, this rather large proportion of ethnic minority patients in 
Singapore could also contribute substantially towards the difference in survival between 
Singaporean and SEER patients.  
Singapore is a developed country with healthcare facilities and access to chemotherapy, 
biological therapy and surgical interventions being at par with other developed countries 
[175]. However, lack of disease awareness and benefits of adherence to treatment need to 
be addressed in order to decrease  the annual number of cancer related deaths even 
though the annual number of new cases is stable or rising [217]. The fall in deaths from 
breast cancer as seen in many countries [230] can be attributed to improved survival from 
a combination of earlier diagnosis [231], improved screening [57] and better treatment 
[232]. Among Singaporean patients, there is room for improvement in the management of 
breast cancer as evidenced from the fact that 22.4% of the excess mortality among 
Singaporean patients could have been reduced had the SEER survival rates been reached. 
This excess mortality among Singaporean patients can be largely attributed to the large 
proportion (9.2%) of the patients receiving non standard treatment. 
We do acknowledge that it is not only stage at presentation that impacts survival and 
several factors like tumor characteristics, treatment and patients‘ attitude towards the 
disease all affect survival, but, a shift in stage at presentation towards earlier stages would 
account for a proportion of deaths being avoided nonetheless.  
We acknowledge that our study suffers from several limitations. The tertiary teaching 
hospital in Singapore sees about 10% of all breast cancer patients in Singapore and using 
data from a hospital based registry in Singapore might not allow us to generalize the 
79 
 
findings to the general population of the country. Secondly, our study is limited by short 
follow up time of the patients. Thirdly, complete information on ER status for the SEER 
patients was not available. However, the reported difference in proportion between ER 
negative patients from the two countries was large suggesting that Singaporean patients 
in general do present with more ER negative disease than the SEER patients. We do 
acknowledge that residual confounding could also partly explain the differences in 
survival between the two countries. The increased diagnostic intensity in USA as 
compared to Singapore will capture ‗healthier‘ patients within the early stage strata (stage 
I and II) resulting in better survival of American patients. However, this effect is likely to 
be very small. Lastly, the impact of certain factors on survival such as SES, treatment 
compliance and cultural and financial barriers to treatment among Singaporean patients 
was not assessed due to lack of data availability. 
Conclusion: 
Singaporean breast cancer patients tend to present at an earlier age and with late stage 
disease as compared to their American counterparts. A stage shift by early detection 
could significantly reduce the burden of the disease in Singapore. In order to reduce the 
excess mortality among Singaporean patients, their within stage survival differences need 
to be reduced. This can be partly achieved by improving the patients‘ treatment and 
creating awareness regarding compliance to treatment and its benefit in terms of survival. 
Possible benefit of early detection and broadening health seeking behavior among 
Singaporean breast cancer patients are issues that need to be addressed and the possible 
reasons for excess mortality are questions worth exploring in future research. 
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Chapter 5 Breast cancer among elderly Singaporean women 
Impact of older age on presentation, management and outcome of breast cancer  
in the multi-ethnic Asian population of Singapore 
(Published as ―Impact of older age on presentation, management and outcome of breast 
cancer in the multi-ethnic Asian population of Singapore.‖ In the Journal of Geriatric 
Oncology 2011) 
Introduction 
Breast cancer is the most common type of cancer and the most common cause of cancer 
death among women worldwide [233]. Breast cancer is a disease of the elderly [15, 16] 
with a majority of Caucasian patients being over 65 years of age at diagnosis [17, 18]. In 
contrast to Europe and the US, where breast cancer incidence rates have stabilized or 
even decreased, Asian breast cancer rates are increasing dramatically [144, 188, 234]. 
With the Westernization of Asian countries, one can expect this trend to continue and it is 
not unthinkable that in the relatively near future, the majority of breast cancer patients 
will be of Asian ethnicity. In Singapore, breast cancer incidence rates have tripled over 
the past three decades [5] and today a Singaporean woman has a lifetime risk of 1 in 20 to 
develop breast cancer [38]. Singapore has seen a shift in peak age of incidence from the 
mid forties to late fifties [37]. With the increasing incidence of breast cancer in general, 
the shift towards the older age groups and the aging population (Figure 5.1), it is crucial 
to have a good understanding of breast cancer in older Asian women.  
Elderly patients are more likely to receive non standard treatment [235]. Reasons for this 
include the higher prevalence of co-morbid conditions, the assumption among clinicians 
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that breast cancer in older women is less aggressive than that in younger women and their 
limited life expectancy, thereby decreasing the perceived benefit of adequate treatment. 
Since older women are less likely to participate in clinical trials [236], little evidence 
exists on optimal treatment for elderly women. 




Several observational studies have suggested that non standard treatment of older breast 
cancer patients strongly impairs their outcome [107, 219, 237]. Until now, characteristics 
of older patients, the degree of non standard treatment and the impact on outcome have 
82 
 
hardly been studied in an Asian setting. The purpose of this study was to examine 
differences in tumor characteristics, treatment and survival among older and younger 
female breast cancer patients in Singapore. 
Patients and Methods 
For this study we used data from the Breast Cancer Registry of the National University 
Hospital (NUH), one of two tertiary teaching hospitals in Singapore [38]. The Breast 
Cancer Registry was established in 1995, through prospective data collection on 
demographics, tumor characteristics, treatment and follow up of all patients presenting 
with invasive or in situ breast cancer. Data from 1990 to 1995 was collected 
retrospectively from medical records. The Breast Cancer Registry has been approved by 
the NUH Institutional Ethics Review Board. NUH followed a standard management 
protocol, based on international guidelines, throughout the study period. 
In this study we included all women diagnosed with primary invasive or in situ (ductal 
carcinoma in situ only) breast cancer between 1990 and 2007 aged 40 years or above (N 
= 2195). Variables of interest included age at diagnosis (continuous), year of diagnosis 
(1990-1995, 1996-2000, 2001-2005, 2006-2007), ethnicity (Chinese, Malay, Indian, 
others), stage (0, I, II, III, IV, unknown) [238], estrogen receptor (ER) and progesterone 
receptor (PR) status (positive, i.e.,  >10% of the tumor cells expressing ERs or PRs, 
negative or unknown), lymphovascular invasion (LVI) (yes, no, unknown), histology 
(ductal, lobular, mucinous, others, unknown), tumor grade (good, moderate, poor, 
unknown), number of lymph nodes excised and number of positive lymph nodes  (0, 1-3, 
4-9, ≥ 10 nodes in accordance with the TNM nodal staging classification [238]). Tumor 
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characteristics were based on surgically removed specimens. For patients not undergoing 
surgery, tumor characteristics were determined from core biopsy specimens. Treatment 
variables in the study were surgery (mastectomy, breast conserving surgery, no surgery) 
radiotherapy (yes, no), chemotherapy (yes, no) and hormone therapy (yes, no).  
We divided patients into two age categories <65 years and ≥ 65 years at diagnosis and 
compared sociodemographic and tumor characteristics and treatments received. To assess 
the level of standard/adequate treatment we compared the proportion of invasive breast 
cancer patients treated with surgery, the proportion receiving radiotherapy following 
breast conserving surgery (BCS), the proportion of estrogen receptor (ER) positive 
patients receiving hormonal therapy, the proportion of ER negative and lymph node (LN) 
positive patients receiving chemotherapy and the proportion of women with invasive 
breast cancer who underwent axillary clearance. These analyses were repeated after 
excluding stage IV patients. This was done to minimize discrepancies as there are no 
―standard treatment‖ guidelines for patients with stage IV disease. 
Statistical analysis 
We performed univariate logistic regression analysis to identify sociodemographic, tumor 
and treatment characteristics that were significantly associated with older age. 
Subsequently we applied multivariate logistic regression analysis to identify which 
factors were independently and significantly associated with older age. 
We calculated relative survival rates (RSRs) to estimate the excess mortality among the 
patient population due to breast cancer [239]. Population mortality data for Singapore 
was used to compute these estimates. Relative survival is defined as the ratio of the 
proportion of observed survivors in a cohort of cancer patients to the proportion of 
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expected survivors in the background population with same age and period distribution 
[156]. The formulation is based on the assumption of independent competing causes of 
death. The relative survival adjusts for the general survival of the Singapore population 
for that race, sex, age and year. Thus the relative survival is a net survival measure 
representing cancer survival in the absence of other causes of death. 
With Cox proportional hazard analysis we determined the association between type of 
locoregional treatment (i.e., mastectomy, BCS plus radiotherapy, BCS alone or no 
surgery) and overall risk of death for the younger and older age groups adjusting for other 
prognostic factors and after testing for proportionality. 
Relative survival analyses were carried out using STATA (version 10) and all other 
analyses were carried out using SPSS (version 16). 
Results 
Of the 2195 patients in our study, 1869 (85.1%) patients were 40 to 64 years old and 326 
(14.9%) patients were 65 years or older. In general, older patients had more missing 
information on the various patient and tumor characteristics than younger patients (Table 
5.1).  
Patient and tumor characteristics and treatment 
 In univariate analysis, ethnicity, stage, LVI, ER status, number of lymph nodes excised 
were associated with older age. In multivariate analysis we found that older patients were 
more likely to present with advanced stage disease (stage IV) than their younger 
counterparts (odds ratio [OR], 1.6; 95% CI, 1.0 to 2.6) and less likely to present with 
early stage disease (stage 0 OR, 0.2; 95% CI, 0.1-0.6 and stage I OR, 0.7; 95%CI, 0.5 to 
1.0).   
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Table 5.1 Patient and tumor characteristics by age and the likelihood of these 
characteristics being associated with old age as determined by logistic regression.  
Variable 
  
≥ 65 yrs 
n=326 
< 65 yrs 
n=1869 
 
Unadjusted OR  
(95%CI) 
 
Adjusted OR       
(95%CI) 
Ethnicity*     
Chinese 277 (85%) 1473(78.8%) 1 1 
Malay 20 (6.1%) 197(10.5%) 0.5(0.3-0.9) 0.5(0.3-0.9) 
Indian 13 (4%) 105(5.6%) 0.7(0.4-1.3) 0.7(0.4-2.5) 
Others 16 (4.9%) 94(5%) 0.9(0.5-1.6) 0.7(0.3-1.2) 
Stage*^     
0 15(4.6%)  194(10.4%) 0.5(0.2-0.8) 0.2(0.1-0.6) 
1 58 (17.8%) 454(24.3%) 0.8(0.5-1.1) 0.7(0.5-1.0) 
2 117 (35.9%) 760(40.7%) 1 1 
3 38 (11.7%) 240(12.8%) 1.0(0.6-1.5) 1.0(0.6-1.5) 
4 53 (16.3%) 123(6.6%) 2.7(1.9-4.0) 1.6(1.0-2.6) 
Unknown 45 (13.8%) 98(5.2%) 2.9(1.9-4.4) 1.7(1.0-3.0) 
Lymphovascular invasion*     
Yes 179(54.9%) 1035(68.9%) 1 1 
No 78(23.9%) 221(11.8%) 1.9(1.3-2.8) 2.4(1.4-4.2) 
Unknown 69(21.2%) 343(18.4%) 1.3(0.9-1.8) 1.1(0.7-1.8) 
Histology*     
Ductal 248(76.1%) 1562(83.6%) 1 1 
Lobular 12(3.7%) 88(4.7%) 0.6(0.3-1.3) 0.5(0.2-1.1) 
Mucinous 9(2.8%) 33(1.8%) 1.7(0.8-3.9) 1.5(0.7-3.5) 
Other 25(7.7%) 121(6.5%) 1.5(0.9-2.4) 1.4(0.9-2.3) 
Unknown 32(9.8%) 65(3.5%) 2.6(1.5-4.3) 1.3(0.7-2.4) 
Number of positive lymph 
nodes*#+   
  
0 nodes 116(63%) 777(59.5%) 1 1 
1-3 nodes 34(18.4%) 279(22.2%) 0.7(0.4-1.1) 0.7(0.5-1.2) 
4-9 nodes 22(12.0%) 155(11.7%) 0.9(0.5-1.5) 0.9(0.5-1.6) 
>=10 nodes 12(6.6%) 87(6.6%) 0.9(0.4-1.8) 1.0(0.5-2.1) 
Unknown 142(43.6%) 553(26.9%) 1.3(1.0-1.8) 0.5(0.1-1.5) 
Tumor Size*+     
<2 cm 73(22.4%) 562(30.1%) 0.7(0.5-1.0) 0.6(0.4-0.9) 
2-5 cm 86(26.4%) 450(24.1%) 1 1 
>5 cm 16(4.9%) 114(6.1%) 0.7(0.3-1.3) 0.7(0.3-1.4) 
Unknown 151(46.3%) 743(39.7%) 1.0(0.7-1.3) 0.6(0.4-1.0) 
ER Status*#     
Negative 67 (28.8%) 628(44.0%) 1 1 
Positive 165 (71.2%) 797(56.0%) 1.9(1.3-2.6) 2.6(1.7-3.8) 
Unknown 94 (28.8%) 444(23.8%) 1.8(1.2-2.5) 2.8(0.4-19.3) 
PR Status     
Negative 97 (29.8%) 639(34.2%) 1 1 
Positive 133 (40.8%) 775(41.5%) 1.0(0.7-1.3) 0.6(0.4-0.9) 
Unknown 96(29.4%) 455(24.3%) 1.1(0.8-1.6) 0.4(0.1-2.9) 
Grade+     
Good 43 (13.2%) 200(10.7%) 1 1 
Moderate 99 (30.4%) 640(34.2%) 0.6(0.4-0.9) 0.8(0.5-1.2) 
Poor 91 (27.9%) 587(31.4%) 0.6(0.4-1.0) 0.9(0.6-1.5) 
Unknown   93 (28.5%)   442(23.6%)    0.8(0.5-1.2)            0.7(0.4-1.2) 
* Variable is significant.    
# Valid percentage has been calculated (i.e., not considering “unknown”). 
^ Unadjusted and Adjusted OR included stage 4 patients. 
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All other Odds Ratios (ORs) and confidence intervals (CIs) have been calculated after excluding stage IV patients. 
+ Logistic regression model adjusted for ethnicity, year of diagnosis, lymphovascular invasion, histology, ER and PR 
status. 




Older patients were more likely to present with ER positive tumors (OR, 2.6; 95% CI, 1.7 
to 3.8). Tumor grade, histology, progesterone receptor status and number of positive 
lymph nodes were not independently associated with older age. 
 
Elderly patients were less likely to undergo breast conserving surgery than younger 
patients (OR, 0.4; 95% CI, 0.3 to 0.7) (Table 5.2) and this difference was more 
pronounced for stage 1 disease (Figure 5.1).  Types of surgical treatment as well as 
receipt of adjuvant treatment were significantly associated with age, with older patients 
being less likely to receive BCS, radiotherapy and chemotherapy (Table 5.2). There were 
217 patients treated with neoadjuvant chemotherapy (38 elderly and 179 young patients). 
Sixty percent (60%) of these elderly patients proceeded to undergo surgery as compared 
to 85% of the younger patients receiving neoadjuvant chemotherapy. Of the patients not 
receiving radiotherapy (247 elderly and 983 young patients), 62% of the elderly and 








Table 5.2 Treatment for patients stratified by age and the likelihood of treatment being 
associated with old age as determined by logistic regression. 
Variable ≥ 65 yrs                          
n =326 




Adjusted OR (95%CI) 
Surgery type*     
Mastectomy 216 (66.3%) 1191(63.7%) 1 1 
BCS 59 (18.1%) 579(31.0%) 0.5(0.3-0.7) 0.4(0.3-0.7) 
No 














































































 * variable is significant. 
All ORs and CIs have been calculated after excluding stage IV patients. 
All ORs are adjusted for ethnicity, year of diagnosis, lymphovascular invasion, histology, ER and 
PR status, stage. 
 
 
Older patients with non-metastasized invasive breast cancer were less likely to undergo 
axillary dissection as compared to the younger patients (Figure 5.2). Among the patients 
with stage 1-3 disease treated with breast conserving surgery, 54.7% of older women 








Figure 5.2  Age  stratified differences in proportion  of: stage 1 patients receiving BCS, 
patients receiving BCS and radiotherapy, ER negative LN positive patients receiving 
chemotherapy and ER positive patients receiving hormonal therapy, all patients 




Similarly older women with ER negative, lymph node positive breast cancer were less 
likely to receive chemotherapy than younger patients (OR, 0.06; 95% CI, 0.01-0.2). In 
contrast, among women with ER positive tumors, equal proportions of old and young 
patients received hormonal therapy (88.7% vs 86.8% respectively).  
 
A quarter of the elderly patients did not receive standard locoregional treatment (defined 
as tumorectomy without radiotherapy or no surgery) as compared to 10.9% of the 









































by stage and the far majority of older and younger women underwent surgery for stage I-
III disease. 
Figure 5.3 Patients with invasive breast cancer treated with tumorectomy without 
radiotherapy or no surgery according to stage and age. 
 
 
 Relative survival 
Overall, the median follow up time was 2.33 years (8 days to 15.7 years). Older patients‘ 
5 and 10 year relative survival (RS) was lower than that of younger patients (65.8% vs 
76.5% for 5 year RS and 48.5% vs 60.6% for 10 year RS respectively) (Figure 5.4). After 
stratification by stage, the differences in 5 and 10 year relative survival between the two 




























* p value <0.001 
90 
 
Table 5.3 Relative survival estimates by stage and age. 
  5 Year Relative Survival 10 Year Relative Survival 
  <65 Years ≥ 65 Years <65 Years ≥ 65 Years 
Overall 76.5% (73.4% - 79.3%)  65.8% (56.0% - 74.8%)  60.6% (55.6% - 65.3%)  48.5% (32.1% - 65.9%)  
Stage 1 100% (97.0% - 101.3%) 98.2% (68.0% - 111.7%) 97.6% (88.2% - 101.6%) 99.9% (58.6% - 140.5%) 
Stage 2 82.9% (78.6% - 86.6%) 77.7% (61.7% - 90.3%) 60.3% (52.8% - 67.1%) 61.5% (33.3% - 87.9%) 
Stage 3 46.0% (36.0% - 55.6%) 40.6% (19.6% - 63.3%) 24.3% (10.9% - 40.8%) 20.7% (3.9% - 51.6%) 
Stage 4 12.7% (6.1% - 21.8%) 23.0% (8.1% - 44.6%) 10.1% (3.9% - 19.8%) 7.1% (0.5% - 22.9%) 
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The risk of death among both age groups was highest in women who did not undergo any 
surgical intervention (Table 5.4), the relative risk being higher for the younger breast 
cancer patients. 
Table 5.4 Hazard ratios for all cause mortality by various surgical treatment options for 
all patients with invasive breast cancer (excluding stage IV patients). 
Treatment type Overall adjusted 
HRs 
Adjusted HRs by age 
  <65 yrs ≥ 65 yrs 
BCS + RT 1 (reference) 1(reference) 1(reference) 
Mastectomy 1.8(1.2-2.6) 1.8 (1.2-2.9) 1.2 (0.5-3.1) 
BCS alone 3.4(1.7-7.1) 4.5 (1.8-11.4) 1.0(0.2-3.8) 
No surgery 6.3(3.4-11.8) 6.7 (3.1-14.8) 2.4 (0.7-8.6) 
BCS: Breast Conserving Surgery, RT: Radiotherapy, HR: Hazard Ratio. 
Adjusted for: Ethnicity, ER status, grade, stage and number of regional nodes positive.  
 P values for overall and <65 yrs groups were <0.001. 
 
Patients receiving breast conserving surgery followed by radiotherapy had the lowest risk 
of death for both age groups. 
Discussion: 
This study shows important differences in tumor characteristics and treatment between 
older and younger breast cancer patients in the Asian setting. Older women were more 
likely to be diagnosed at advanced stages and had more often ER positive tumors. Older 
patients were less likely to receive standard treatment and had overall lower relative 
survival estimates. 
In general, our findings are in concordance with other studies on elderly women, most of 
which were conducted in the West [240-242].  Similar to what has been reported in 
Caucasian studies, our results emphasize that there is room for improvement in the 
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management of Asian elderly breast cancer patients. First of all a lower proportion of 
breast cancer in the elderly was detected at an early stage while a large proportion 
presented with distant metastases. This could be the result of patient delay, reduced 
awareness among the elderly [221] or higher prevalence of fatalistic views. Other 
explanations could be the fact that breast screening in Singapore is relatively new and 
attendance rates are low [55]. Older women could be more hesitant to undergo 
mammographic screening for cultural or personal issues and this could have led to a 
decrease in the detection of early breast cancers. Presenting with advanced disease could 
reflect the elderly patients‘ attitude towards the disease and possible fear or anxiety of 
treatment. Since older women were less likely to present with lymphovascular invasion 
and had similar grade distribution, it is unlikely that increased aggressiveness of breast 
tumors caused the advanced stage at diagnosis.   
There is a large volume of evidence showing that elderly patients are less likely to 
receive standard treatment for breast cancer [236, 243-246].  In Caucasian populations it 
has been observed that older women are less likely to be treated surgically, even though 
they tolerate mastectomy and breast conserving surgery just as well as younger patients 
[247]. Omission of surgery for older women has been associated with increased risk of 
local recurrence and death from breast cancer [107]. We noted that non-standard 
locoregional treatment (tumorectomy without radiotherapy or no surgery was associated 
with an increased risk of death, and this effect was stronger in younger women. The far 
majority of patients in our study underwent surgery and mastectomy was the most 
common form of surgery for both age groups. Even though elderly patients were overall 
less likely to receive surgical treatment than younger patients, stage stratification showed 
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that they were just as likely as younger patients to receive surgery for stage I-III disease. 
It was difficult to gauge the impact of chemotherapy for LN positive patients or BCS for 
stage 1 disease on survival (for each age group) as the number of elderly patients were 
too small within each subgroup. 
Optimal adjuvant treatment regimens for older breast cancer patients are still debated. 
Studies have shown diminishing benefits of chemotherapy with increasing age [232] and 
the underrepresentation or even exclusion of elderly patients in clinical trials has led to a 
huge gap in available evidence in this field. In our study, use of hormonal treatment was 
similar among the younger and older age groups but older women were less likely to 
receive chemotherapy for ER negative, lymph node positive tumors. This could reflect 
physicians‘ decision not to administer radiotherapy or chemotherapy, taking into account 
toxicity profiles of the drugs and patient co-morbidities. Other explanations for the 
omission of adjuvant treatment include the patient or family members‘ wish not to treat 
[219, 237] based on financial or cultural reasons, lack of social healthcare system in 
Singapore and the fact that very few people have health insurance. Transportation to 
hospitals and clinics in our opinion would not be a major deterrent as distances are fairly 
short in Singapore and public transport is efficient and reliable. 
Relative survival analysis showed that elderly breast cancer patients had lower 5 and 10 
year overall relative survival rates indicating more breast cancer related deaths occurred 
in the elderly patients. These survival differences were mainly attributed to differences in 
stage distribution as they practically disappeared after stratification by stage. This is in 
contrast to the Caucasian setting where age differences in survival persist after stage 
stratification [223, 248]. Lead time bias could also account for the differences in survival 
94 
 
as the elderly patients are less likely to undergo mammographic screening resulting in a 
lower number of breast cancer cases being detected early as compared to younger 
patients. 
  Adequate loco-regional treatment (i.e., breast conserving surgery followed by 
radiotherapy or mastectomy) is associated with a reduced risk of local recurrence [249] 
and all cause mortality [107]. We found that patients underwent inadequate loco-regional 
treatment, i.e. breast conserving surgery without radiotherapy or no surgery at all were at 
a significantly increased risk of death as compared to patients who underwent adequate 
loco-regional treatment. The association between overall mortality and type of breast 
cancer treatment was present in both age groups but the increment in risk with inadequate 
loco-regional treatment was higher for younger patients suggesting that under treatment 
may be especially detrimental in younger age groups. It was difficult to gauge the 
differences in survival between patients receiving chemotherapy for LN positive patients 
or BCS for stage 1 disease on survival for each age group as the number of elderly 
patients were too small within each subgroup. Residual confounding is very likely to play 
a role, as unmeasured factors like co-morbidity or general health status may have 
influenced the decision not to operate or irradiate.  
We acknowledge that our study has several limitations. Firstly, being a hospital based 
study rather than a population based study, extrapolation of our findings to the general 
population might not be appropriate. The National University Hospital treats an estimated 
10% of breast cancer cases in Singapore [38]. The demographics of the patients and 
catchment area that NUH serves are not different from other areas of the country [38]. 
Thus, even though extrapolation of our results to the general population might not be 
95 
 
appropriate, the NUH data did give a good idea of Singaporean breast cancer patient and 
tumor characteristics. Secondly, our study is also limited by the small sample size of 
elderly patients and limited follow up time. However, the small proportion of elderly 
patients in our study can be partly explained by the fact that Singapore has an age 
distribution that is predominantly young with a majority of the population being below 
the age of 65 years.  Also, the Singapore Cancer Registry data showed that during the 
period of 1990-2002, 18% of the female breast cancer patients were ≥65 years of age at 
diagnosis[40]. Hence we would expect a larger proportion of patients to be diagnosed 
under the age of 65 years. Although the proportion of elderly patients in our study was 
15%, we did manage to display important differences in tumor characteristics and 
treatment between the old and young patients. Thirdly, lack of co-morbidity data and 
patient background information such as residential status, educational level and family 
income could have led to residual confounding. The impact of this missing information 
on treatment decisions and patient survival will be difficult to gauge. Lastly, being an 
observational study, there was the possibility of selection bias. 
Conclusion: 
Our study shows that older Asian breast cancer patients are diagnosed at later stages than 
younger women. However our results suggest that older age in itself is not independently 





Chapter 6 Lymph node ratio as a prognostic indicator 
Does the axillary lymph node ratio have any added prognostic value over pN staging for 
Singaporean and Malaysian breast cancer patients? 
(Accepted for publication as ―Does the axillary lymph node ratio have any added 
prognostic value over pN staging for South East Asian breast cancer patients? in PLOS 
ONE 2012) 
Introduction 
Axillary lymph node status is one of the most important prognostic factors for breast 
cancer [19-21] . Traditionally, axillary lymph node status is classified according to the 
American Joint Committee on Cancer (AJCC) breast cancer staging system, which is 
based on the number of positive axillary lymph nodes [250] where pN0 indicates zero 
positive nodes, pN1 1-3 positive nodes, pN2 4-9 positive nodes and pN3: ≥10 positive 
nodes.  This pN stage is restricted by the number of nodes excised [251] which in turn 
depends upon the surgical approach to axillary dissection, the expertise of the surgeon as 
well as the pathologists‘ experience and thoroughness. Variation in these factors can lead 
to large differences in the number of lymph nodes retrieved across institutions thereby 
influencing staging.  
Increasing evidence suggests that the Lymph Node Ratio (LNR) (the ratio of the number 
of positive nodes to the total number of nodes excised), is a superior prognostic indicator 
compared to the absolute number of nodes involved [22-26]. However some studies have 
shown no difference in prognostic value for LNR over pN [252]. Vinh Hung et al showed 
that LNR, categorized as low > 0 and <0.2, intermediate 0.2 to 0.65 and high risk >0.65 
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to 1, was better at predicting breast cancer specific mortality than pN staging [22]. This 
conclusion was based on the fact that confidence intervals for the adjusted hazard ratios 
did not overlap for the intermediate and high risk LNR groups but did so for the pN2 and 
pN3 groups. A study from Korea showed no overall difference between LNR and pN 
staging in categorizing poor, intermediate and good survivors, except for certain 
subgroups, i.e. women aged <35 years, HER2 over expressing and triple negative 
tumors[26]. Other studies conducted in different populations also suggested that LNR 
was a significant and independent predictor of outcome for breast cancer patients [10, 23-
25, 142]. 
Prognostication, however, is a multivariable process, as the outcome of a disease is 
determined by a variety of (sometimes interacting) factors, and breast cancer is no 
exception. In addition to axillary lymph node status, prognosis is determined by a variety 
of factors, including, age, tumor size, grade, receptors status and treatment. Despite the 
large number of studies that have addressed LNR, not one has assessed the added 
prognostic value of LNR over pN in predicting overall survival after breast cancer. 
Methods: 
Data for this study was obtained from the Singapore Malaysia Hospital based Breast 
Cancer Registry [1]. This registry combines data from the National University Hospital 
(NUH) breast cancer registry, Singapore and the University of Malaya Medical Center 
(UMMC) breast cancer registry, Kuala Lumpur, Malaysia. 
The NUH breast cancer registry started in 1995 and contains information on 2,449 
consecutive breast cancer patients diagnosed between 1990 and 2007. The UMMC breast 
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cancer registry started in 1993 contains information on 3,320 patients diagnosed between 
1993 and 2007. Details on both these registries are described elsewhere [1, 38]. In both 
centers, patients were monitored through follow-up in the specialist outpatient clinics. 
Data on mortality were obtained from the hospitals‘ medical records and by linkage with 
the respective death registries. Follow up for each patient was calculated from the date of 
diagnosis to the date of death or end of follow up (July 2010 for NUH patients and 
November 2010 for UMMC patients). Both the registries had approval from their 
respective ethics review boards. 
We selected women diagnosed with non metastatic primary invasive breast cancer, with 
information on the number of excised and the number of positive axillary lymph nodes. 
Patients receiving neoadjuvant chemotherapy (N=312), patients with a node negative 
(pN0) axilla (N=2352), patients with missing information on exact number of lymph 
nodes involved  (N=664), with in situ breast cancer (N=317) and stage IV disease 
(N=535) were excluded. In total 1589 patients were included for analysis.  
Information recorded for each patient included age at diagnosis, ethnicity (Chinese, 
Malay, Indian or others), year of diagnosis, place of diagnosis (Singapore, Kuala 
Lumpur), date of death or date of last contact . Tumor characteristics included tumor size 
( <2 cm, 2-5 cm, >5 cm, unknown), estrogen (ER) and progesterone receptor (PR) status 
(positive i.e., ≥10% of epithelial tumor cells expressing receptors, negative and 
unknown), grade (good, moderate, poor, unknown). In terms of axillary dissection, we 
collected information on total number of axillary nodes examined and number of positive 
axilary nodes. LNR was categorized into three categories including, low (>0 and <0.2), 




Life table analysis was performed to calculate survival probabilities for the three pN 
categories and the three LNR categories. After testing for proportionality, we performed 
univariate Cox proportional hazards analysis to identify variables that were significantly 
associated with all cause mortality. For details on Cox proportional hazards analysis, 
refer to chapter 3.  Multivariate Cox proportional hazard analysis was applied (1) to 
calculate adjusted mortality risks and (2) to identify which combination of factors, 
including pN or LNR that best predicted overall survival. Internal validation of the 
models was done by bootstrap resampling. From the final model, adjusted Hazard Ratio 
for pN were derived and by replacing pN with LNR, we obtained adjusted HRs for the 
three LNR categories.  
In order to ascertain the added prognostic value of LNR over pN, we compared the 
discriminative capacity of the two models. Discrimination indicates how well the model 
is able to distinguish between patients who will experience the outcome (death) and those 
who will not. Discrimination was assessed by the Concordance (c) statistic, the 
interpretation of which is equivalent to the area under the receiver operating characeristic 
curve, that is, a c statistic of 0.5 indicates no discrimination above chance, whereas a c 
statistic of 1.0 indicates perfect discrimination. Comparison of c statistics between the 
model including LNR  with the one including pN staging tells whether one model is 
better in discriminating between poor and good survivors, and thus superior in predicting 
survival. Model calibration—the agreement between predicted risks and observed 
mortality risks—was assessed by comparing the predicted survival and the observed 
survival at 3-year follow-up. 
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After a recent publication suggested that LNR is particularly informative in subgroups of 
patients (i.e. patients with unfavorable tumor characteristics and younger patients) we 
performed subgroup analyses by age (<60 years and ≥60 years), receptor status (ER- vs 
ER+) and grade (1, 2 and 3) [26].  
Finally, the c statistic has been criticized for being insensitive in comparing models and 
for having little direct clinical relevance. Therefore, we calculated the Net 
Reclassification Improvement (NRI), which assesses the ability of a model including a 
new prognostic marker to more accurately reclassify individuals into higher or lower risk 
strata. The NRI is the difference in proportions of patients moving up and down risk 
strata (high, moderate and low risk of mortality) among patients with the event of interest 
versus those without (in our case patients who died within 3 years of follow up versus 
those who survived). The NRI is similar to the simple percentage reclassified but 
distinguishes between movements in the correct direction (up for case patients (deaths) 
and down for control patients (survivors) [165]. Based on their individual survival 
probabilities we categorized patients into lower tertile, middle tertile and upper tertile for 
risk of death at 3 years of follow up. 
 All analysis were performed using STATA version 11. 
Results 
According to the LNR classification, 758 (47.7%) patients were categorized as low risk 
(>0 and <0.2), 574 (36.1%) as intermediate risk (0.2 to 0.65) and 257 (16.2%) as high 
risk (>0.65 to 1)LNR. For classic pN staging, 879 (55.2%) were pN1, 447 (28.1%) pN2 
and 263 (16.7%) pN3 (Table 6.1). Five year survival probabilities for the patients 
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stratified by LNR were 79%, 70% and 43% for low, intermediate and high risk groups 
respectively (Table 6.2). Five year survival probabilities for the patients stratified by pN 
classification were 79%, 65% and 48% for pN1, pN2 and pN3 respectively (Figure 6.1).  





In univariate Cox regression analysis, age at diagnosis, place of diagnosis, year of 
diagnosis,  ethnicity, receptor status (ER and PR), treatment, grade, stage,  tumor size, pN 
staging were independently and significantly associated with all cause mortality (Table 
6.1). After multivariate analysis, a model consisting of  pN, age, tumor size, tumor grade, 
chemotherapy,  radiotherapy, and surgery, gave the best fit.  Taking pN1 patients as a 
reference, adjusted mortality risks (Hazard Ratios) were 1.9 (95%CI, 1.5 to 2.3) for pN2 
patients and 3.0 (95%CI, 2.4 to 3.7) for pN3 patients. Similarly, compared to patient 
classified as low risk LNR (>0 and <0.2), those with intermediate risk LNR had an HRadj 
of 1.5 (95%CI, 1.2 to 1.9) and those with high risk LNR an HRadj of 3.2 (95%CI, 2.6 to 
4.0) (Table 6.2).  
Both models (including pN and LNR respectively) were well calibrated (p-value Hosmer 
Lemeshow test 0.67 and 0.83 respectively). In terms of discriminating ability, both 
models performed equally well, as shown by the c statistic for model including LNR of 
0.73 (95% CI 0.71 to 0.76) and c statistic for the model including pN stage of 0.72 (95% 
CI 0.70 to 0.75). The substantial overlap between the two 95% confidence intervals 
indicated that LNR did not provide any added prognostic value when compared to pN 









Table 6.1 Patient, tumor characteristics and treatment along with the unadjusted Hazard 
Ratio for all cause mortality for Malaysian and Singaporean patients. 
Variable N (%) Unadjusted HR 
(95% CI) 
P value of 
unadjusted HR 
Age in years 
Median (Range) 
<40 years 
40 to 49 years 
50 to 59 years 
≥ 60 years 
 








0.7 (0.5 to 0.9) 
1.0 (0.8 to 1.3) 














1.5 (1.1 to 1.9) 
1.2 (1.0 to 1.5) 












0.5 (0.4 to 0.7) 












0.4 (0.3 to 0.6) 













0.4 (0.2 to 0.7) 
1 
1.4 (1.1 to 1.6) 













0.5 (0.4 to 0.7) 
1 
1.6 (1.3 to 2.0) 






























0.5 (0.4 to 0.6) 
<0.001 












1.8 (0.9 to 3.3) 
1.0 (0.8 to 1.2) 
1 
0.151 













1.7 (1.4 to 2.1) 
3.3 (2.6 to 4.1) 
<0.001 













1.5 (1.2 to 1.8) 
3.6 (2.9 tp 4.5) 
<0.001 




Subgroup analysis showed that LNR was superior to pN staging in categorizing patients‘ 
risk of death for patients aged 60 years and above, patients with ER negative tumors and 
patients with high grade tumors, as for these subgroups, 95% confidence intervals (CIs) 
for intermediate and high risk LNR groups did not overlap while they did for the pN2 and 
pN3 categories. However, in terms of discriminating capacity, models including LNR 
performed similarly well as models including pN, as attested by the c statistics and 
largely overlapping 95% CIs (Table 6.3). There was no significant difference in risk 
stratification between LNR and pN staging for women <60 years, ER positive and low / 
moderate grade tumors (Table 6.3). 
Table 6.2 Survival probabilities and Hazard Ratios for all cause mortality by pN 
classification and Lymph Node Ratio(LNR) 
Variable N (%) N 
Dead 
5 year Survival 





















79.0% (75.6% to 82.4%) 
65.0% (59.0% to 71.0%) 
48.0% (43.2% to 52.8%) 
 
1 
1.7 (1.4 to 2.1) 
3.3 (2.6 to 4.1) 
 
1 
1.9 (1.5 to 2.3) 
3.0 (2.4 to 3.7) 
0.72 
 














79.0% (75.4% to 82.6%) 
70.0% (65.2% to 74.8%) 
43.0% (33.0% to 53.0%) 
 
1 
1.5 (1.2 to 1.8) 
3.6 (2.9 to 4.5) 
 
1 
1.5 (1.2 to 1.9) 
3.2 (2.6 to 4.0) 
0.73 
 
(0.71 to 0.76) 
*Each model is adjusted for: age, radiotherapy, ethnicity, surgery type, grade and tumor size and stratified by ER Status 
Both models were internally validated using bootstrap resampling. 
 
Based on individual predicted survival probabilities (from both pN staging and LNR 
models), when patients were categorized into lower tertile, middle tertile, and higher 
tertile for risk of death, the LNR model additionally classified 8.0% (n=49) of patients 
with the event (death) into higher risk groups and 4.5% (n=29) of the patients with the 
event into low risk groups. Among the patients without the event (alive), an additional 
5.6% (n=52) of patients were classified into lower risk groups while 5.7% (n=53) of the 
patients without the event were classified into high risk groups  than the model with pN 
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staging So overall, the model including LNR reclassified 3.2% more patients in the 
correct risk groups than the model including pN, but the Net Reclassification 










Patients ≥ 60 years of age at diagnosis (N=325) 
 
















2.8 (1.8 to 4.1) 
4.2 (2.7 to 6.3) 
 
1 
2.7 (1.8 to 4.1) 
4.2 (2.6 to 6.7) 
0.75 (0.70 to 0.81) 
Lymph Node Ratio 
Low ≤0.20 








1.6 (1.0 to 2.4) 
5.2 (3.4 to 7.8)  
 
1 
1.8 (1.1 to 2.7) 
4.5 (2.8 to 7.0) 
0.76 (0.71 to 0.80) 
 
Patients with ER negative tumors at diagnosis (N=662) 
 
















2.0 (1.5 to 2.6) 
3.1 (2.3 to 4.3)  
 
1 
2.0 (1.5 to 2.7) 
3.0 (2.1 to 4.1) 
0.84 (0.80 to 0.87) 
Lymph Node Ratio 
Low ≤0.20 








1.4 (1.0 to 1.9) 
3.7 (2.7 to 4.9) 
 
1 
1.5 (1.1 to 2.0) 
3.5 (2.5 to 4.8) 
0.85 (0.81 to 0.88) 
 
Patients with high grade tumors at diagnosis (N=635) 
 
















1.6  (1.2 to 2.1) 
2.6 (1.9 to 3.5) 
 
1 
1.7 (1.2 to 2.3) 
2.6 (1.9 to 3.5) 
0.76 (0.72 to 0.80) 
Lymph Node Ratio 
Low ≤0.20  








1.3 (1.0 to 1.7) 
2.9 (2.1 to 3.1) 
 
1 
1.4 (1.1 to 1.8) 
2.7 (2.0 to 3.7) 





Table 6.3 Contd. 
 
Patients < 60 years of age at diagnosis (N=1264) 
 
















1.5 (1.2 to 1.9) 
2.7 (2.1 to 3.4) 
 
1 
1.6 (1.3 to 2.1) 
2.6 (2.0 to 3.5) 
0.71 (0.68 to 0.74) 
Lymph Node Ratio 
Low ≤0.20 








1.4 (1.1 to 1.7) 
2.9 (2.2 to 3.6)  
 
1 
1.6 (1.2 to 2.2) 
2.9 (2.2 to 3.9) 
0.70 (0.66 to 0.72) 
 
Patients with ER positive tumors at diagnosis (N=844) 
 
















1.5 (1.1 to 2.1) 
2.9 (2.1 to 3.8) 
 
1 
1.6 (1.2 to 2.3) 
2.9 (2.1 to 4.1) 
0.74 (0.71 to 0.79) 
Lymph Node Ratio 
Low ≤0.20 








1.6 (1.2 to 2.0) 
2.6 (1.9 to 3.6) 
 
1 
1.8 (1.3 to 3.4) 
2.9 (2.0 to 4.2) 
0.75 (0.70 to 0.77) 
 
Patients with moderate andlow grade tumors at diagnosis (N=788) 
 
















1.9 (1.4 to 2.5) 
3.1 (2.3 to 4.3) 
 
1 
2.0 (1.5 to 2.7) 
3.3 (2.4 to 4.6) 
0.70 (0.66 to 0.73) 
Lymph Node Ratio 
Low ≤0.20  








1.8 (1.3 to 2.3) 
3.4 (2.3 to 3.7) 
 
1 
1.9 (1.4 to 2.5) 
3.4 (2.4 to 4.8) 
0.69 (0.66 to 0.73) 
 
a Model adjusted for age at diagnosis, chemotherapy, radiotherapy, surgery type, grade and tumor size and stratified by ER status 
bModel adjusted for age at diagnosis, chemotherapy, , surgery type and tumor size 
c Model adjusted for age at diagnosis, chemotherapy, radiotherapy, surgery type and tumor size and stratified by ER status 
All models were internally validated using bootstrap resampling. 
 
Although a majority of the patients (~83%) did have at least ten lymph nodes examined, 
about 17% of the patients had less than 10 nodes removed during axillary dissection. We 
performed a subgroup analysis to assess the added prognostic value of LNR for patients 
with less than 10 nodes and for this subset of patients, pN staging was better at 




Table 6.4 Risk reclassification table at 3 years of follow up based on models including 













Middle tertile Higher 
tertile 
Total 
Lower tertile 127 24  151 
Middle tertile 23 335 25 383 
Higher tertile  6 65 21 




Lower tertile 405 45  450 
Middle tertile 48 396 8 452 
Higher tertile  4 16 20 
Total 453 445 24 922 




Table 6.5 Multivariate Cox regression analysis for all cause mortality for patients with 
less than ten nodes retrieved. 
 














2.8 (1.9 to 4.1) 
 
1 
2.9 (1.8 to 4.6) 
0.71  
(0.65 to 0.78) 
Lymph Node Ratio 
Low ≤0.20 








1.1 (0.7 to 1.8) 
3.3 (2.0 to 5.4) 
 
1 
1.1 (0.6 to 1.8) 
1.2 (1.8 to 5.5) 
0.70  
(0.65 to 0.77) 
 
aModel adjusted for age at diagnosis, chemotherapy, radiotherapy, surgery type, grade and tumor size and stratified by ER status 
 
 
Several cut off points for LNR were explored but no new cut off points were established 
for our cohort of patients. 
Discussion 
This study shows that pN staging is comparable to LNR in predicting  overall survival of 
women with breast cancer, with the exception of patients aged 60 years or more, patients 
with ER negative tumors and patients with high grade tumors. Here, LNR was superior in 
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categorizing patients into intermediate and high risk strata as compared to pN stage. 
However, in combination with other prognostic factors, LNR did not provide any 
additional prognostic information over pN staging, neither for the entire cohort, nor for 
the subgroups of older women and those with ER negative of grade 3 tumors. The 
observation that LNR was not superior to the pN staging was seen in other Asian studies 
as well [26].  A non significant Net Reclassification Index for the LNR model compared 
to the pN model suggested that replacement of pN by LNR would not lead to better 
classification of patients into appropriate risk strata.  
The number of lymph nodes retrieved and examined is highly dependent on  surgical 
expertise,  the institution‘s protocol and the pathologists‘ experience [253]. Removal of at 
least ten axillary lymph nodes is considered adequate for reliable lymph node staging 
[254-256]. In the current study, 17% of the patients had less than 10 nodes removed 
during axillary dissection. For this subset of patients, pN staging was better in 
categorizing patients into different risk strata as compared to LNR but there was no 
significant difference in the discriminative power of the two multivariate models (one 
with LNR and one with pN).  
The implications of our study have been put into a different light by recent studies, which 
have indicated that full axillary clearance following a positive sentinel node biopsy does 
not affect survival in certain (low risk) categories of breast cancer patients [118, 257]. 
These studies may induce a shift towards less axillary clearances following sentinel node 
biopsy in the future. However, in many low and middle income countries, sentinel node 
biopsies are not routinely available. Also, Asian women present with more advanced 
disease, larger tumor sizes, more nodal metastasis and more high grade tumors, and 
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therefore complete axillary dissection, and complete staging of the axilla, is still very 
relevant in the South East Asian setting [258]. 
We acknowledge that our study suffers from several shortcomings, including a relatively 
short follow up time. In addition, we assessed all cause mortality as our end point as no 
data on cause of death was available. This could have led to a mixing of effects as this 
analysis allowed for competing risks of death. Also, additional information on HER2 / 
NEU receptor status, socioecomonic status and comorbidity could have allowed for a 
deeper understanding of the association. 
Conclusion 
Among South East Asian breast cancer patients, both the Lymph Node Ratio and the pN 
staging system seem to be equally good at predicting all cause mortality. LNR may be 
better than pN in dividing tumors into high vs low risk for certain subgroup of patients, 










Prognostic value of axillary lymph node status after neoadjuvant chemotherapy. 
(Published as ―Prognostic value of axillary lymph node status after neoadjuvant 
chemotherapy. Results from a multicenter study.‖ in the European Journal of Cancer 
2011) 
Introduction 
Administration of neoadjuvant chemotherapy to women with locally advanced breast 
cancer serves not only to convert inoperable to operable disease, but also to increase the 
likelihood of breast conservative surgery [259-263]. Neoadjuvant chemotherapy may 
however modify the yield of involved axillary lymph nodes and may lead to an 
underestimation in prognostic value provided by nodal status [142, 264].  
The number of positive lymph nodes is one of the most important prognostic factors for 
breast cancer [19-21] and to date, the American Joint Committee on Cancer (AJCC) 
staging system is based on the number of positive axillary lymph nodes [250] (ypN0: 
zero positive nodes, ypN1: 1-3 positive nodes, ypN2: 4-9 positive nodes, ypN3: ≥10 
positive nodes).  The number of positive lymph nodes (ypN stage) is however restricted 
by the number of nodes excised [251] which in turn depends upon the surgical approach 
to axillary dissection,  physiological variations between patients as well as the effect of 
neoadjuvant chemotherapy. Variation in these factors leads to large differences in the 
number of lymph nodes retrieved across surgeons as well as institutions thereby 
influencing staging. Thus if a surgeon systematically excised only 8 axillary lymph 
nodes, patients can never be classified as ypN3, potentially resulting in under-staging and 
under-treatment of the patient. Several studies have suggested that the ratio of the number 
111 
 
of positive nodes to the total number of nodes excised, known as the lymph node ratio 
(LNR), is a superior prognostic indicator than the absolute number of nodes [22-25]. 
Being a ratio, the LNR accounts for the discrepancies that might arise due to differences 
in the technique of axillary dissection across institutions. 
In this study, we evaluated the prognostic value of lymph node status in patients treated 
with neoadjuvant chemotherapy and assessed whether LNR was superior to the absolute 
number of lymph nodes involved in predicting overall survival.  
Patients and Methods 
For this study we combined data from three sources, i.e. the National University Hospital 
(NUH) Breast Cancer Registry in Singapore, University of Malaya Medical Centre 
(UMMC) Hospital Based Registry in Kuala Lumpur, Malaysia and the population-based 
Geneva Cancer Registry, Switzerland.  
The NUH Breast Cancer Registry was described previously [38]. In summary, this 
registry was established in 1995, through prospective data collection on demographics, 
tumor characteristics, treatment and follow up of all patients presenting with invasive or 
in situ breast cancer. Data from 1990 to 1995 was collected retrospectively from medical 
records. Vital status information for a majority of the patients was determined through 
long term NUH follow up clinics. For those patients that did not regularly follow up at 
NUH, contact was made via telephone of letter annually. Death information was obtained 
from the physician and hospital records and Hospice Associations.  Patients were 
followed to death or end of follow up (31
st
 December, 2008), whichever came first. The 
Breast Cancer Registry has been approved by the NUH Institutional Ethics Review 
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Board. The UMMC Hospital Based Registry has been prospectively compiling patient 
and tumor characteristics for all patients diagnosed with breast cancer starting from 1993. 
Mortality data was updated by direct linkage with the Malaysian National Registry 
Department. This registry has been approved by the UMMC Institutional Ethics Review 
Board. Patients were followed to death or end of follow up (31
st
 April, 2010), whichever 
came first.  
The Geneva Cancer Registry records information on all newly diagnosed cancer cases 
arising in the Swiss canton of Geneva (population approximately 430,000). The 
registration is based on several sources of information and is extremely accurate, as 
attested by its low percentage (<2%) of cases recorded from death certificates only [265]. 
Patients were followed to death or end of follow up (31
st
 December, 2008), whichever 
came first. All hospitals, pathology laboratories, and private practitioners in the canton 
are requested to report all cancer cases. Trained tumor registrars systematically abstract 
data from medical and laboratory records. Physicians regularly receive inquiry forms to 
complete missing clinical and therapeutic data. The Geneva Cancer Registry regularly 
assesses survival, taking as reference date the date of confirmation of diagnosis or the 
date of hospitalization (if it preceded the diagnosis and was related to the disease). In 
addition to passive follow-up (standard examination of death certificates and hospital 
records), active follow-up is performed yearly using the files of the Cantonal Population 
Office (office in charge of the registration of the resident population). 
For the current study, we selected women diagnosed with primary invasive breast cancer, 
receiving neoadjuvant chemotherapy followed by surgery and with information on the 
number of excised and the number of positive axillary lymph nodes. Patients with distant 
113 
 
metastases and patients not undergoing surgery were excluded from the study. All cause 
mortality of the selected patients was assessed. From the 2545 patients in the NUH breast 
cancer registry databse, 156 (6.1%) patients received neoadjuvant chemotherapy  and of 
these, 136 (5.3%) with complete information on excised and positive lymph nodes were 
included in the analysis. Similarly, from the 1001 patients diagnosed in Kuala Lumpur , 
71 (7.0%) underwent neoadjuvant chemotherapy for locally advanced disease and of 
these 51 (5.0%) patients with complete information on excised and positive lymph node 
were included in the analysis. Of the 5236 patients in the Geneva Cancer Registry, 133 
(2.5%) received neoadjuvant chemotherapy and for 127 (2.4) patients we had complete 
information on . In total, 314 patients were included for analysis.  
Information recorded for each patient included age at diagnosis, ethnicity (Asian versus 
Caucasian/other), nationality, year of diagnosis, place of diagnosis (Singapore, Geneva or 
Kuala Lumpur), date of death or date of last contact . Tumor characteristics included 
tumor size based on prechemotherapy and was categorized into  less than 2 cm, 2 to 5 
cm,  greater than 5 cm and unknown, stage (based on prechemotherapy - 1, 2, 3, 
unknown), estrogen (ER) and progesterone receptor (PR) status (positive i.e., ≥10% of 
immune-reactive neoplastic cells expressing receptors, negative and unknown), 
differentiation (good, moderate, poor, unknown -based on the Scarff-Bloom-Richardson 
grading scheme [85]  ), were recorded for all patients. Treatment information included 
adjuvant radiotherapy (no, yes), adjuvant hormonal therapy (no, yes) and adjuvant 
chemotherapy (no, yes). Axillary dissection information included number of regional 
nodes examined and number of positive regional nodes. All excised axillary noded were 
embedded for analysis. Information on chemotherapy regimens was not available for the 
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Geneva patients. Patients from Kuala Lumpur center received FEC (ie 5-fluorouracil 500 
mg/m2, epirubicin 75 mg/m2 and cyclophosphamide 500 mg/m2) given IV every 3 
weeks for 3 cycles as neoadjuvant chemotherapy. A majority of the patients from 
Singapore received anthracyclines-containing combination chemotherapy with or without 
taxanes as neoadjuvant treatment. None of the patietns in our study underwent sentinel 
lymph node biopsy. 
For the purpose of comparability with the current ypN classification system, LNR was 
categorized into four categories including zero (0), low (>0 and <0.2), intermediate (0.2 
to 0.65) and high risk (>0.65 to 1) groups based on previous findings [22]. These cut off 
points were earlier identified as most optimal cut off levels and internallly validated in a 
population based study (13). Additionally, using three cut off points gave us four 
categories for LNR which facilitated comparison to the four ypN groups. 
Statistics: 
After testing for proportionality, we performed a univariate Cox proportional hazard 
analysis to identify variables that were significantly associated with all cause mortality. 
Subsequently we performed multivariate Cox proportional hazard analysis, to look at the 
association between overall mortality and LNR and ypN respectively using two different 
models with similar adjustments. The first model had LNR as one the independent 
variables and the second model had ypN staging as one of the independent variables. 
We entered all the significant variables (as per table 6.9) into a multivariate Cox model. 
Using backward stepwise selection, we eliminated variables that did not contribute 
significantly to the fit of the model and continued until the model consisted of variables 
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that were significantly associated with all cause mortality. Using this procedure, only 
LNR or ypN, age, PR status, place of diagnosis and radiotherapy were significantly 
associated with all cause mortality. 
The reference category for the models were low risk LNR group and ypN1 group 
respectively as these categories contained the highest number of patients. By using large 
groups as reference categories, we increased the stability of our models. The 
interpretation of our findings would not have changed had we used the ―zero‖ categories 
as the references for the two models. 
 Life tables were computed to gauge the survival probability for the group of patients 
stratified by the different LNR cutoffs and ypN classification.  
Statistical analyses were performed with STATA (version 10) and SPSS (version 16). 
Results 
 The median age of the 314 patients was 48 years (Table 6.6) and the majority  (75.5%) 
had at least 10 axillary lymph nodes examined. All patients had undergone an axillary 
clearance. A large proportion of the patients (88.4%) received adjuvant radiotherapy and 
virtually all patients (98.8%) received adjuvant (completion) chemotherapy , which is 
standard procedure in the respective countries. The median number of involved nodes 






Table 6.6 Patient and tumor characteristics for patients treated with neoadjuvant 
chemotherapy  
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* indicates valid proportion has been calculated (i.e., not considering “unknown”) 
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When using the LNR classification, 88 patients were categorized as zero, 91 as low risk 
(>0 and <0.2), 82 as intermediate risk (0.2 to 0.65)   and 53 as high risk (>0.65 to 1) 
LNR. For classic ypN staging, 88 were ypN0, 126 ypN1, 58 ypN2 and 42 ypN3. Five 
year survival probabilities for the patients stratified by LNR were 84%, 69%, 53% and 
37% for zero, low (>0 and <0.2), intermediate (0.2 to 0.65) and high risk (>0.65 to 1) 
groups respectively (Table 6.8). In comparison to this, the 5 year survival probabilities 
for the patients stratified by ypN classification were 84%, 64%, 57% and 30% for ypN0, 
ypN1, ypN2 and ypN3 respectively (Figure 6.2). 
Table 6.7 Axillary nodal status of the patients treated with neoadjuvant chemotherapy 

































































































In univariate analysis, place of diagnosis, year of diagnosis,  ethnicity, receptor status 
(ER and PR), hormone therapy, differentiation, stage,  tumor size, ypN staging and LNR 












Table 6.8 Survival probabilities by LNR and ypN classification (neoadjuvant 
pathological lymph node status).  
Variable 1 year survival 
probability (95% CI) 
3 year survival 
probability (95% CI) 






Intermediate  >0.20 and ≤0.65 





































Compared to patient classified as low risk LNR (>0 and <0.2), those with LNR zero had 
an adjusted mortality (adjusted hazard ratio [HRadj]) of 0.4 (95%CI, 0.2 to 0.9), those 
with intermediate risk LNR had an HRadj of 1.2 (95%CI, 0.7 to 2.2) and those with high 
LNR an  HRadj of 2.7 (95%CI, 1.5 to 5.0) Similarly, ypN classification adjusted 
mortality risks for ypN0 patients was HRadj 0.3 (95%CI, 0.2 to 0.7) , for ypN2 patients 
was HRadj 1.1 (95%CI, 0.6 to 2.0) and for ypN3 patients was HRadj 2.2 (95%CI, 1.3 to 
3.8) compared to ypN1 patients (Table 6.10).  
Almost a quarter (N= 77) of the patients had less than 10 lymph nodes excised.We 
performed a subgroup analysis to determine whether LNR had better prognostic value 
than ypN for this subset of patients. Compared to patient classified as low risk LNR (>0 
and <0.2) (N=10), the HRadj for LNR zero (N=28) was 0.1 (95% CI, 0.02 to 0.9), 
intermediate risk LNR (N=24) was 0.8 (95%CI, 0.2 to 3.7) and high risk LNR (N=15)  





Table 6.9 Univariate Cox Regression analysis for variables associated with all cause 
mortality for patients treated with neoadjuvant chemotherapy. 
Variable Unadjusted HR  (95% CI) P value 

































































































Low , ≤0.20 





















Similarly, when compared to ypN1 patients (N=36), the HRadj for ypN0 patients (N=28) 
was 0.1 (95%CI, 0.01 to 0.5) and for ypN2 patients(N=13) was 2.1 (95%CI, 0.7 to 6.1).  
Even though it seems that LNR may have some added value over ypN in identifying 
patients at highly increased risk of death, the number of patients in our study was too 
limited to allow firm conclusions for this subset of patients. 
Table 6.10 Hazard ratios for LNR and ypN classification for all cause mortality  
Variable Unadjusted 
HR (95%CI) 
Adjusted HR      
(95%CI) 




Low , ≤0.20 





























HR- Hazard Ratio 
HRs adjusted for Age, PR status, Place of diagnosis and Radiotherapy. 
 
Discussion 
The results of this study show that axillary nodal status of patients treated with 
neoadjuvant chemotherapy is strongly associated with overall mortality. Both the 
absolute number of positive lymph nodes involved (current ypN staging) as well as the 
LNR are among the strongest prognostic factors in this patient category. LNR and ypN 
classification were comparable in predicting mortality in this group of patients. 
The past few decades has seen a rapid rise in the role and complexity of neoadjuvant 
chemotherapy for breast cancer [266]. Neoadjuvant chemotherapy enables doctors to in 
vivo monitor the response to chemotherapy [267], although it is not associated with 
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improved survival as compared to adjuvant chemotherapy [267, 268].  The broader use of 
neoadjuvant chemotherapy has led to challenging complexities in breast cancer staging. 
Clinical staging, i.e., preoperative staging based on clinical and radiographic examination 
and pathological staging, i.e., postoperative staging based on lymph node involvement 
and tumor size might vary significantly for patients who have responeded well to 
neoadjuvant chemptherapy [269]. It is unclear whether the initial clinical staging or the 
final pathological staging is more meaningful in terms of prognosis and treatment options 
for patients receiving neoadjuvant chemotherapy [269] and the effect of neoadjuvant 
chemotherapy on lymph node involvement is still uncertain. The number of lymph nodes 
retrieved and examined is highly dependent on  surgical expertise,  the institution‘s 
protocol and the pathologists‘ experience [253]. Removal of at least 10 axillary lymph 
nodes is considered adequate for reliable lymph node staging [254-256]. In the 
neoadjuvant setting, certain studies have shown that patients undergoing neoadjuvant 
chemotherapy have a significantly lower number of lymph nodes excised compared to 
patients undergoing surgery without preoperative chemotherapy [270, 271] while another 
study concluded otherwise [251]. Since the number of positive lymph nodes is one of the 
most important and well established prognostic factors in patients treated with primary 
surger it is important for us to elucidate its role in the neoadjuvant setting. 
To date only one comprehensive study has looked at the prognostic value of the lymph 
node ratio in the neoadjuvant setting [142]. This study concluded that the LNR was an 
independent prognostic factor for relapse free and overall survival. Another study (only 
presented in abstract form [272]) also looked into the prognostic value of the LNR in the 
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neoadjuvant setting and also concluded that LNR was a significant prognostic factor for 
overall survival and superior to ypN. 
 Our research indicates that patients with higher LNR had a poorer survival probability 
which was in accordance with other studies [22, 24, 143, 273]. On comparing the current 
ypN classification and LNR, we did not notice substantial differences in hazard ratios for 
all cause mortality. Even though it seems that for patients with less than 10 lymph nodes 
removed, LNR may have some added value over ypN in identifying patients at highly 
increased risk of death, the number of patients in our study was too limited to allow firm 
conclusions for this subset of patients. 
Patients from Singapore and Kuala Lumpur presented with larger tumors that were more 
often poorly differentiated as compared patients from Geneva. Although the median 
number of positive nodes for the three centers was the same, a greater proportion of 
patients from the Singapore and Kuala Lumpur center were categorized into the ypN2 
and ypN3 categories than patients from the Geneva center. This could suggest that larger 
tumor size led to greater number of lymph nodes being involved as seen from the 
Singapore and Kuala Lumpur centers which is in accordance with previous studies [274].  
This is one of the first studies indicating that lymph node status, be it ypN or LNR, is of 
prognostic value in patients treated with neoadjuvant chemotherapy. Even though several 
studies in the non-neoadjuvant setting have shown that the LNR is a superior prognostic 
indicator than the current ypN staging [22-25], our findings do not support this. 
We acknowledge that our study suffers from several shortcomings, including a limited 
number of patients and a  relatively short follow up time. In addition, we assessed all 
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cause mortality as our end point as no data on cause of death or local recurrence were 
available. Lastly, the lack of information on variables like HER2/ NEU receptor status 
and socio-economic status left room for residual confounding. During our period of 
study, the South East Asian institutes (Kuala Lumpur and Singapore) followed a different 
pattern of chemotherapy administration as compared to the regimens adopted in Western 
countries. Although the chemotherapy regimens have now been redesigned in these 
institutes, we do agree that the difference in chemotherapy regimens could limit our 
findings. 
 The strength of this study lies in the fact that it is an international multicenter study. Data 
from the three registries were merged, justified by the similar distribution of age and 
tumor characteristics. Secondly, detailed information on treatment and tumor 
characteristics was available.  
Conclusion 
This international multicentre study shows that lymph node status after neoadjuvant 
chemotherapy is informative. In the neoadjuvant setting, lymph node ratio does not seem 







Chapter 7 Conclusion 
This thesis looks at clinical outcomes of breast cancer patients from Singapore and 
Malaysia. Although outcome of Singaporean breast cancer patients was better than the 
Malaysian counterparts, there is still some way to go before Singaporean patients can 
achieve survival rates observed in the SEER population. 
Elderly Singaporean patients present with advanced stage disease and are less likely to 
receive adequate treatment compared to the younger patients. Elderly patients were also 
more likely to have poorer relative survival overall but this difference substantially 
reduced after stage stratification. 
Based on the results from the LNR studies, it is clear that cut off points for LNR 
established in Geneva, Switzerland do not add any prognostic value over the current pN 
staging system for Singaporean and Malaysian patients. Further work looking at factors 
such as SES, education, treatment compliance, method of breast cancer detection, 
housing type and cultural and financial barriers and their impact on survival need to be 
addressed. 
The overall burden of breast cancer is shifting substantially to vulnerable populations in 
ill-prepared developing countries. In the past few decades, Asia has seen rapid economic 
growth resulting in increasing life expectancies, declining mortality from infectious 
diseases and Westernization of lifestyles. A consequence of such changes has been an 
increase in breast cancer incidence across Asia with rates increasing by up to 30% in the 
last decade for countries like India and China. Singapore has seen a threefold increase in 
incidence rate from 1968 to 2007. These alarming statistics added to the fact that Asia is 
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the most populous of continents seems to suggest that a majority of new breast cancer 
cases will arise from Asia in the near future. 
With the growing global heath inequalities, very little attention is being paid to the rising 
toll of cancer patients in developing countries. Today, a person‘s odds of surviving after 
cancer diagnosis or even receipt of appropriate treatment, including basic palliative care, 
is strongly correlated with where that person live [275]. With the globalization of breast 
cancer, it is essential for us to focus on Asian women, who are relatively understudied. It 
is common practice among both clinicians and researchers to superimpose findings 
conducted in the Western populations, onto other ethnic groups. This might not be a 
rational approach given the differences in life expectancy, socioeconomic status, 
lifestyles, culture, diet and health beliefs among Western and Asian women as these 
factors may contribute towards breast cancer incidence and prognosis. 
Conducting clinical research in Asia is not only about gaining knowledge but also about 
transforming daily clinical practice and guiding policy makers to perform heath 
transformation and rethink their funding priorities. With the rapid industrialization of 
most Asian countries, breast cancer will soon be one of the leading causes of death 
overtaking infectious diseases in Asia and it is essential for governments in developing 
Asian countries to be equipped for this. An estimated 1.7 million cases of breast cancer 
will arise in 2020 with a majority of the cases being from developing countries [14]. 
Experts have warned that most of these nations will not be prepared to face this crisis as 
they do not have the infrastructure in place to prevent cancer, diagnose it early or provide 
long term treatment [275]. 
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Although breast cancer incidence is lower in Asian countries as compared to the West, 
this should not be an excuse for inaction [12]. Branding breast cancer as ―low priority‖ 
[276] will not benefit any nation and affirmative action needs to be taken immediately. 
Although international expert groups like Breast Health Global Initiative [12] and 
CanTreat International [275] have been lobbying to improve cancer prevention and 
control in developing countries, it should be the governments that proactively take action 
to combat cancer. Action in breast cancer prevention should encompass all areas such as 
improving early detection, imparting knowledge about the disease to the general 
population, providing access to adequate treatment and long term follow up as well as 
palliative care when necessary. The aim of this approach is to improve the survival rates 
and quality of life of Asian patients with breast cancer. 
Breast cancer in Asian women – what can clinicians and researchers do? 
National breast cancer registries are needed to facilitate health services planning and 
policy making. Where such registries don‘t exist yet or are in their infancy, hospital based 
registries could be used as a guide to establish the population based registries. 
The Singapore Malaysia Breast Cancer Working Group hospital based Breast Cancer 
Registry was a first step in achieving the goal mentioned above [1]. To date, the registry 
contains information on over 6000 consecutive patients from two tertiary teaching 
hospitals namely, National University Hospital, Singapore and University of Malaya 
Medical Center, Kuala Lumpur, Malaysia. Over the past two years, members of this 
working group have performed various studies, among others, determining the prognostic 
factors for survival in Asian women with breast cancer [277, 278], validating prognostic 
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classification systems such as Lymph Node Ratio [32] and Adjuvant! Online [139] for 
Asian women, studying the impact of age on presentation, management and outcome of 
breast cancer among South East Asian women [32, 278]. 
Further studies focusing on studying the economic burden of the disease in South East 
Asia as well as improving patient quality of life and overall healthcare need to be 
conducted with special attention being paid to better understanding the root cause for 
poor survival in developing Asian countries. Studies looking at patients‘ outlook towards 
the disease and treatment selection and adherence and how this impacts survival, what 
underlying cultural beliefs lead women to present at late stages with large tumors – 
factors associated with delayed presentation among Asian women, possible explanations 
and implications of delayed treatment or non compliance to treatment due to cultural or 
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